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ABSTRACT 
This thesis covers different aspects of glucose and fat metabolism and of the interplay 
between the two metabolic pathways. The glucose and fat metabolism and mechanisms 
involved in the regulation have been investigated through the formulation of four 
mechanistic models and one simple allometric model, each covering different aspects of 
the metabolism. The goal of the modelling efforts is not primarily to predict but rather to 
explain the behavior of and test various hypotheses about the involved biological 
/physiological processes and mechanisms, with a view to gain a better understanding of 
the human glucose and fat metabolism.  
  
The formulation of a quasi steady state model of the flows and transformations in human 
glucose and fat metabolism was used to illustrate the importance of the interplay between 
glucose and fat metabolism. The regulation of glucose and fat metabolism is complex and, 
combined with at simple model of hexokinase, the glucose and fat steady state model 
illustrate how important it is not only to focus on the uptake of glucose into the cell but 
also to consider how the utilisation of intercellular glucose in regulated. Simulation of 
hyperinsulinemic glucose clamp studies with the glucose and fat metabolism steady state 
model showed that that the nutritional state of the metabolism can influence the 
conclusion of an experimental glucose clamp study. The clamp simulation also showed 
that changes in the regulation of lipid metabolism influence the glucose utilisation rate at 
lower insulin levels.  
 
Through the construction of a model of hepatic glucose metabolism I found that both 
stimulation of glycogen synthesis by glucose and inhibition of glycogen breakdown by 
glucose were necessary in order to explain the experimentally observed relation between 
hepatic glucose output and plasma glucose concentration (45). The hepatic glucose 
metabolism model was also used to test the effect of either glycogen stimulation of its 
own breakdown or glycogen inhibition of its own synthesis. It was found that both 
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mechanisms separately could explain the experimentally observed linear relation between 
net glycogen breakdown and hepatic glycogen content experimentally observed (77;106).  
 
Through the formation of a model of postprandial plasma non-esterified fatty acid 
dynamics, the mechanism involved in the experimental observed plasma non-esterified 
fatty acid overshoot in the late postprandial period was investigated. Simulation with this 
the model showed that the stimulatory effect of insulin on lipoprotein lipase, and 
especially the long response time for this effect, is the main mechanism responsible for 
the observed overshoot. The postprandial plasma non-esterified fatty acid dynamics model 
was used to simulate plasma non-esterified fatty acid profile for healthy as well as for 
obese and diabetic subjects. Regulation of adipose tissue lipase by insulin was found to be 
essential in explaining the differences in the plasma non-esterified fatty acid profiles in 
relation to plasma insulin profiles observed in studies of postprandial metabolism. The 
model indicated a relation between overnight fasted insulin concentration and half 
maximal suppression insulin concentration for adipose tissue lipase (EC50).    
 
A small model describing the allometric relationship between changes in visceral fat and 
total fat mass was made. This is the first model to reveal an allometric relationship 
between changes of visceral and total fat mass that holds for both genders as well as for a 
wide range of weight loss interventions including bariatric surgery, caloric restriction with 
or without exercise, and exercise alone. From this relationship it can be concluded that 
changes of visceral fat are primarily determined by total fat mass changes and by the 
initial visceral to total fat mass ratio. For future investigations of visceral fat loss the 
allometric model predictions could be used as a null hypothesis to test for an additional 
independent effect of weight loss.  
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DANSK OPSUMERING / DANISH SUMMERY 
Denne ph.d afhandling omhandler forskellige facetter af det menneskelige glukose og fedt 
stofskifte. Glukose og fedt stofstiftet og de fysiologiske mekanismer, som regulerer 
stofskiftet, er blevet undersøgt gennem beskrivelsen af fire mekanisme-baserede modeller 
samt en simple allometrisk model. Målet med modellerne er ikke kun at forudsige, men 
også at forklare dynamikken af og teste hypoteser om de involverede 
biologiske/fysiologiske processer og mekanismer, for derved opnå en større forståelse af 
det menneskelige glukose og fedt stofskifte. 
 
Beskrivelsen af en steady state model af glukose og fedt metabolismen blev brugt til at 
illustrere hvor vigtig samspillet mellem glukose og fedt stofskiftet er. Regulering af 
glukose og fedt stofskiftet er meget kompleks, og sammen med en simpel model at 
hexokinase blev glukose og fedt steady state modellen brugt til at vise, hvor vigtigt det er 
ikke kun at fokusere på optaget af glukose i cellerne, men også på hvordan forbruget af 
glukose i cellerne bliver reguleret. Simuleringer af hyperinsulinemic glukose clamp 
studier med glukose og fedt steady state modellen viste, at den ernæringsmæssige tilstand 
af metabolismen kan have indflydelse på resultatet af glukose clamp studier. Desuden 
viste simuleringerne at ændringer i fedt stofskiftet kan have indflydelse på størrelsen af 
glukose forbruget for lavere insulin niveauer.  
 
Gennem beskrivelsen af en model af lever glukose stofskifte har jeg vist at både en 
stimulering af lever glykogen syntesen af glukose og en hæmning af lever glykogen 
nedbrydningen af glukose er nødvendig for at forklare det eksperimentelt fundne forhold 
mellem leverens glukose produktion og plasma glukose koncentration under forhold med 
basale insulin og glukagon niveauer (45). Lever glukose stofskifte modellen blev også 
brugt til at teste om en mekanisme hvor lever glykogen stimulerer sin egen nedbrydning, 
eller en mekanisme, hvor lever glykogen hæmmer sin egen syntese, kan forklare det 
lineære forhold mellem net lever glykogen nedbrydning af lever glykogen niveau som er 
observeret eksperimentelt (77;106). Gennem denne undersøgelse blev det vist at begge 
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mekanismer hver for sig kunne forklare det observerede forhold mellem net glykogen 
nedbrydning og glykogen niveau.  
 
Ved hjælp af en model, der beskriver plasma fedtsyre dynamikken efter et måltid, har jeg 
undersøget, hvilke mekanismer der er med til at give den eksperimentalt observerede 
plasma fedtsyre over kompensation i den sene fase efter et måltid (43;86;113). Denne 
undersøgelse viste, at den observerede overkompensation i plasma fedtsyre kan forklares 
gennem insulin stimulering af nedbrydningen af plasma triglycerid til fedt syre 
(lipoprotein lipase), samt den lange tids forskydning (omkring 4 timer) denne stimulering 
sker under. Med den beskrevne model af plasma fedtsyre dynamikken efter et måltid 
kunne jeg reproducere plasma fedtsyre tidsserier efter et måltid for både normale, 
overvægtige og diabetiske personer. For overvægtige og diabetiske personer krævede det 
dog ændringer af et mindre antal model parametre. Gennem simuleringen af plasma 
fedtsyre dynamikken efter et måltid, blev det fundet at insulin regulering af fedtvævets 
frigivelse af fedtsyre (adipose tissue lipase) er afgørende for at forklare de forskelle 
mellem plasma fedtsyre profiler efter et måltid som kan observeres for normale, 
overvægtige og diabetiske personer. Desuden indikerede model simuleringer en relation 
mellem den basale insulin koncentration (efter en nats faste) og den insulin koncentration 
der giver halv maksimal hæmning på adipose tissue lipase (EC50). 
 
Under mit ophold ved NIH har jeg været med til at opstille en lille model, der beskriver 
det allometriske forhold mellem ændringer i visceral fedt og total fedtmasse. Modellen er 
den første, der afslører et allometrisk forhold mellem ændringen i visceral fedt masse og 
total fedt masse, som gælder for begge køn, samt for mange forskellige vægt tabs 
metoder, herunder reduktion af mave sækkens volumen, kalorie restriktion med og uden 
motion samt motion alene. Gennem dette allometriske forhold kan det konkluderes, at 
ændringer i visceral fedt masse primært er bestemt af ændringen i total fedt masse samt af 
det initiale forhold mellem visceral fedtmasse og total fedtmasse. For fremtidige 
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undersøgelser af visceral fedttab kan den allometriske model bruges som nul hypotese til 
at teste for, om der er en ekstra uafhængig effekt af et vægttab, på visceral fedttab.    
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1 INTRODUCTION 
The food composition and the content of carbohydrate, fat and protein in the food differ 
considerably from person to person and from culture to culture. The human metabolism 
must be able to cope with them all; sometimes immediately and sometimes after a period 
of adaptation. The nutrients are broken down in the intestine and appear in the blood 
mainly as glucose, amino acids, and fatty acids coupled to albumin or triglycerides stored 
in the lipoproteins. The blood transports the nutrients – or metabolites of the nutrients – 
from organ to organ, and the different organs collaborate in the utilization of the nutrients 
for energy needs, building or replacement of cells and tissues, and storage. The storage 
option is important, since food intake is discontinuous with intervals of hours or even 
days, so in some periods the uptake from the intestine exceeds the organism’s demands 
and in other periods there is no uptake, and the organism must rely on its nutrient stores. 
Consequently there is interchange of nutrients and metabolites back and forth, and the 
regulation of this traffic is one of the major challenges of our metabolic control. In the 
blood, glucose concentration is held within narrow limits. The fasting plasma glucose is 
normally 4-5 mM (66), and even during large meals, the increase is only a few mM in 
healthy persons and lasts only for a few hours. In contrast, the concentration of fatty acids 
varies from up to around 1.5 mM during long fast (66) to 0.1 mM after a meal (66). Both 
the glucose and the fatty acid metabolism are mainly controlled by the hormone insulin, 
although insulin in not released in response to a signal related to fatty acid metabolism, at 
lease not directly.  So it appears to be a fair conclusion that insulin is controlling the 
plasma glucose concentration and that the effect on fatty acids is secondary to the glucose 
control. The view has led to the notion that the insulin-glucose system acts as an isolated, 
classic control system to keep the plasma glucose constant. If the glucose concentration 
increases, the beta cells release more insulin that increases the glucose uptake mainly in 
muscle, and decreases the hepatic glucose output, so the glucose concentration is brought 
down again. However, the fate of the glucose is complex, and the control of the 
intracellular utilisation may be even more important than the regulation of the glucose 
uptake. The glucose and fat should rather be thought of as a complex system that controls 
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the detailed metabolic interchange, and where the movements of fatty acids play an 
integral role.     
 
Experiments on isolated organs, tissues and cells have contributed significantly to our 
understanding of the metabolic system. However, glucose and fat homeostasis requires 
integrated control by the whole organism, and the used of biosimulation can help us to 
gain insight into the complex regulation of the metabolism, by combining our 
physiological knowledge in mechanistic models.   
 
1.1 BIOSIMULATION 
To improve the understanding of physiology, diseases and drug action one can introduce 
physiology or mechanism based models. This approach will be referred to as 
biosimulation. Mechanism based models describes the dynamics of a system expressed by 
the physiological processes and interaction we know or assume exists in the biological 
system. This is done by translating knowledge about biological systems into mathematical 
expressions. The relevant biological processes and mechanisms are represented as 
realistically as possible, and parameters and relations are determined from independent 
experiments. Beside experience with mathematical modelling, this approach requires a 
good overview of the relevant literature and an extensive biochemical and physiological 
expertise as well as mathematical. It is also important that the modelling work is 
preformed in close collaboration with scientists or clinicians who can perform the relevant 
experiments. The mechanistic models are validated by their ability to reproduce observed 
phenomena and to predict the outcome of other experiments. Biosimulation can be used to 
increase our understanding of complex biological systems, predictions (“what if 
scenarios”) and test hypotheses about possible biological processes and mechanisms 
involved  
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The models described in the thesis are ordinary differential equations models, where each 
differential equation represents a metabolite or hormone. The descriptions of metabolic 
fluxes are in general formulated in terms of the rate determining steps of a process. The 
metabolic fluxes are by and large expressed as Michaelis-Menten type functions. The 
kinetic parameters are found in the literature, when possible. It has not been possible to 
find values for all relevant kinetic parameters. Hence, the values are estimated based on 
measured rates of the metabolic fluxes and estimated concentrations of the metabolites, 
and relations between fluxes.  
 
The models described in this thesis are set up in MATLAB R2008b student edition and 
solved using MATLAB solver ode45 and ode15s.   
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1.2 THESIS OBJECTIVES AND OUTLINES 
Through the formulation of physiological mechanistic models, this thesis will investigate 
the regulation and interplay between the metabolism of glucose and fat. The goal is not 
only to predict specific outcomes, but also to explain the general behaviour of the systems 
and to test hypotheses about biological /physiological processes and mechanisms, all in 
view of gaining a better understanding of the human glucose and fat metabolism.  
 
The first section; “The Interplay between Glucose and Fat” is concerned with the 
relationship between glucose and fat metabolism, and the utilisation of the two 
metabolites. Through formulation of a glucose and fat metabolism steady state model and 
simulation of glucose clamp studies it is first illustrated how important the interplay 
between the two metabolic pathways is for the selection of nutrition used for oxidation, 
and for the way the two metabolic pathways indirectly influence each others dynamics. To 
further illustrate the importance of metabolite utilisation, a simple model of hexokinase is 
described. This model captures a mechanism not described in the glucose and fat steady 
state model, namely the reduced glucose uptake by cells without intercellular glucose 
utilisation.     
 
In the second section “Hepatic Glucose Metabolism” a model of the hepatic glucose 
metabolism is described. The model looks into possible mechanisms involved in the 
regulation of hepatic glucose production during fasting. Focusing on how glucose 
regulates its own hepatic production, and how the hepatic glycogen content is involved in 
this regulation. In relation to the interplay between glucose and fat metabolism the hepatic 
capacity for glucose production during fasting and its capacity for glycogen storages have 
impact not only on glucose metabolism, but also on the utilisation of glucose, and thereby 
also indirectly on insulin, fat metabolism.  
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The section “Postprandial Lipid Metabolism” focuses on the dynamics of postprandial 
plasma non-estrified fatty acids after a meal, especially on the late postprandial plasma 
fatty acid overshoot. The overshoot is observed 6-8 hours after a meal is given, under 
normal conditions a new meal would be consumed before the overshoot is observed. 
However, this overshoot might be able to explain why the dynamics of glucose, insulin 
and fatty acids of the second meal is different from that of the first meal. This is why it is 
relevant to look into the mechanism responsible for this late postprandial fatty acid 
overshoot. The model was used to simulated studies of postprandial fatty acid metabolism, 
for different subjects groups, in order to see if the model could reveal any changes in lipid 
metabolism between for example lean, obese and diabetic subjects.  
 
The last section is concerned with the relationship between visceral fat and total fat mass, 
and the changes in the though fat masses associated with weight loss. The model 
described in this section is the first model to reveal an allometric relationship between 
changes of visceral and total fat mass that holds for both genders as well as for a wide 
variety of weight loss interventions including bariatric surgery, caloric restriction with or 
without exercise, and exercise alone. 
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2 THE INTERPLAY BETWEEN GLUCOSE AND FAT 
As mentioned the regulation of the glucose and fat metabolism in very complex, and there 
are several areas where the two metabolic pathways interplay. One of the major regulators 
for both systems are is insulin (66). Insulin regulates the glucose transport into the cells, 
and it regulates the release and uptake of non-esterified fatty acid from adipose tissue, and 
thereby indirectly fatty acid oxidation and glucose oxidation. The literature has a strong 
focus on the glucose uptake, i.e., only the removal of glucose from the blood into the 
cells. This is, however, a too simplified view. The removal takes place mainly by 
facilitated diffusion via special glucose transporters like GLUT1 and GLUT4 (66). Inside 
the cell glucose is phosphorylated to glucose-6-phosphate, which traps the glucose inside 
the cell. Only a few cell types, mainly in the liver and kidney, are able to de-
phosphorylate G6P back into glucose (7;66).  The fate of the G6P is complex and differs 
from cell type to cell type and with the nutritional situation of the body. For an illustration 
 
 
Figure 1: The main routes of glucose breakdown in liver cells, muscle cells and adipocytes.  
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of the routes of glucose utilisation see figure 1. Once glucose is phosphorylated, the 
quantitatively most important fates of glucose 6-phosphate are as follows:  
 
- Oxidation, glucose 6-phosphate enters glycolysis and the Krabs TCA cycle 
to be oxidised into CO2 and H2O.  
- Storages, glucose 6-phophate is stored as glycogen inside primarily the liver 
and muscle cells. The capacity for glycogen storages are limited to about 
500g glucose which is less that a days worth of energy (66).   
- Glucose re-cycling, glucose 6-phosphate can also be converted into lactate. 
In this way excess glucose can escape the cell. Lactate can be taken up by all 
cells in the body, where it can be converted to pyruvate and be utilised. In 
the liver lactate can be transformed back to glucose and re-enter the systemic 
circulation. 
- Fat synthesis, glucose 6-phosphate can also enter glycolysis so that instead 
of oxidation it is used for fat synthesis though de novo lipogenesis.  
 
As mentioned insulin is a major actor in the interplay between glucose and fat 
metabolism. Another major aspect of this interplay is oxidation which, as mentioned, is 
indirectly regulated by insulin. The turnover of non-esterifed fatty acids seems to depend 
more of less on the level of non-esterified fatty acids, at least during rest (64;125). Total 
body energy expenditure is covered by oxidation of fatty acids, glucose and protein. Thus, 
in situations with high fatty acid oxidation the need for glucose oxidation is low, and 
glucose will have to be utilised by other routes. Glucose re-cycling, which normally 
amounts to around 50 g glucose per day (21), gives a possibility to increase the fatty acid 
oxidation in situation of excess glucose. If glucose in the cells are not oxidised or stored, it 
can re-enter the systemic circulation through the cori-cycle (lactate-glucose cycle), and 
thereby stimulate insulin production, which inhibits plasma non-esterified fatty acid 
concentration and thereby fatty acid oxidation.   
 
 18
The effect of insulin on the glucose metabolism is investigated though glucose clamps 
studies, as well as through oral or intravenous glucose tolerance tests (OGTT and 
IVGTT).  In glucose clamp studies, glucose is kept at a constant level by intervenous 
infusion of glucose. The glucose infusion rate (GIR) is used to determine the effect of 
insulin at the given insulin and glucose concentrations. In OGTT’s and IVGTT’s glucose 
in given orally or intravenously, respectively. The plasma response of glucose (AUC) is 
then used to evaluate the effect of insulin. However neither of these tests can tell us how 
the glucose is utilised. Through the formulation of a glucose and fat steady state model, 
the utilisation of glucose is investigated from a more systematic point of view.  
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2.1 GLUCOSE AND FAT STEADY STATE MODEL 
The steady state or quasi steady state is a hypothetical situation in which the daily 
variation in plasma glucose, insulin, triglyceride and non-esterified fatty acids are 
averaged out over the whole day, and so are the metabolic fluxes. The steady state model 
applied to get an overview of how the daily energy intake (in the form of glucose and fat) 
is utilised and to illustrate the complexity of the regulation of glucose and fat metabolism.  
 
 
Figure 2:  Schematic presentation of the glucose fat steady state model. The full line represents fluxes; except 
for glucose stimulatory effect on insulin secretion (broken line) the effectors of the different fluxes are not 
shown.  
 
Part of the steady state model has previous been described in the Master Thesis 
“Modelling the Interplay between the Fat and Glucose Metabolism” by Hallgreen, C.E 
and Nielsen, B (2005). However, the steady state model described in the master thesis has 
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since been modified in several ways in order to describe situations with negative or 
positive energy balance. The following section will start with a short summary of the 
steady state model as describe in my Master Thesis. The parts of the model that has been 
modified will be described more toroughly. Figure 2 shows a schematic overview of the 
steady state model. The circled capitals represent state variables and the full lines 
represent fluxes between the different metabolites. The stimulatory effect of glucose on 
insulin secretion is represented by a broken line, and insulin’s effect on different fluxes 
are shown by + or -, stimulation or inhibition, respectively. The regulatory effects of other 
metabolites on different fluxes are not shown.  
 
The plasma glucose concentration stimulates the production of insulin from the beta-cells 
in pancreas. In this model the secretion of insulin is regulated by plasma glucose 
concentration, this is described through a Hill function. Elimination of insulin occurs in 
liver, kidneys, and fat and muscle cells. The liver is responsible for about 50% of the 
insulin clearance, the hepatic insulin clearance in considered to be saturated as is the 
elimination of insulin by fat and muscle cells (78).   
 
In the steady state model, dietary glucose and fat intakes are considered to be constant 
rates. The rate of dietary glucose is released into plasma as is the rate of dietary fat. Note, 
however that rate of dietary fat is released into plasma as triglycerides.  
 
Triglycerides in the plasma are carried by lipoproteins (66). An example is the 
chylomicrons that are secreted form the intestinal wall, and contain the triglyceride 
entering our system from dietary triglyceride. Another major lipoprotein, referred to as 
very low density lipoprotein (VLDL), VLDL triglyceride is primarily secreted from the 
liver. Other lipoproteins are low density lipoprotein (LDL) and high density lipoprotein 
(HDL). These two lipoproteins carry cholesterol (66). LDL and HDL will not be 
considered further in this model. The Chylomicro-triglyceride and the VLDL-triglyceride 
are hydrolysed by lipoprotein lipase (LPL) to non-esterified fatty acids. Lipoprotein lipase 
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prefers larger particles (66;166), and in comparison to VLDL-triglyceride the  
Chylomicro-Triglyceride are cleared quickly from plasma. The major contribution to 
lipoprotein lipase activity is adipose tissue, although lipoprotein lipase also occurs in 
connection to muscle and liver. Adipose tissue lipoprotein lipase is stimulated by insulin, 
and in the same time insulin also stimulates re-esterification of lipoproteins in to adipose 
tissue. However, there is a spillover of non-esterified fatty acids in to plasma.  
 
Another route for non-esterified fatty acids into plasma is from adipose tissue lipolysis. 
This process is known to be inhibited by insulin and the inhibition is saturated at high 
insulin levels (40;50;66;150). Adipose tissue also takes up plasma non-esterified fatty 
acids. Here they are re-esterified to triglyceride and stored, and this process in stimulated 
by insulin, again the effect of insulin will be saturated at high insulin levels (39;50).   
 
Another fate of plasma fatty acids is to be taken up by different cells for oxidation, 
primarily muscle cells. Under resting condition this uptake is closely related to plasma 
non-esterified fatty acid concentration, and with in the muscle cell fatty acids are oxidised 
in accordance with their rate of uptake (64). 
  
Further more plasma non-esterified fatty acids are taken up by the liver, where they are 
either re-esterified and released into plasma as VLDL-triglyceride, or go through beta-
oxidation to produce ketone bodies, which are important sources for oxidation during 
starvation. In this model the formation of either VLDL-triglyceride or ketone bodies from 
hepatic fatty acid uptake is stimulated and inhibited by insulin, respectively. Ketone 
bodies is either oxidised or eliminated, for example though expiration, both are regulated 
by the availability of ketone bodies (118).  
 
One of the major connections between the glucose and fat metabolism in this model is 
obviously insulin. Insulin secretion is regulated by plasma glucose concentration and as 
mentioned, insulin regulates fat metabolism in several ways, especially by regulating the 
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direction of flux to the adipose tissue. High insulin stimulates triglyceride storing in 
adipose tissue while low insulin favours release of fatty acids into the plasma. But glucose 
and fat metabolism is also connected through oxidation and gluconeogenesis.   
 
In the glucose and fat steady state model, glucose oxidation is the difference between total 
oxidation and lipid and protein oxidation. Protein oxidation is minimum 7% of total 
oxidation, however 50% of protein intake in considered to be oxidised in steady state. The 
other 50% of protein intake is considered to contribute to gluconeogenesis. In the steady 
state model, gluconeogenesis from glycogen is considered to be proportional to lipid 
oxidation (5), this will be explained further later in this section, see “2.1.4 
Glyconeogenesis”. Gluconeogenesis is one of the paths for glucose to enter the system. 
Besides gluconeogenesis from protein and glycerol, glucose is also produced from lactate; 
the rate of gluconeogenesis from lactate is regulated by substrate availability 
 
Glucose is removed from plasma and taken up by different cells through glucose 
transporters. The brain needs a continuous uptake of glucose for oxidation, since it can not 
take up and utilise fatty acids (64). Glucose is transported into the brain cells by the 
GLUT3 glucose transporter. The rate of glucose uptake through GLUT3 is saturated for 
glucose levels within the normal range and and can be described through a Michaelis-
Menten function, with a low Km (66). The effects from insulin are assumed negligible 
(95).  
 
The GLUT1 is another insulin independent glucose transporter. Insulin independent 
glucose transport takes place in muscle cells, adipose tissue, nerve cells and blood cells 
(51). Again the rate of glucose uptake through the transporter is described through a 
Michaelis- Menten function. The GLUT1 glucose transporter has a low affinity for 
glucose (high Km) and is not saturated at glucose concentrations within the normal range 
(66;72).  
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The last glucose transporter described in the model is the GLUT4 glucose transporter. 
This transporter is insulin dependent. Insulin increase the glucose transport by GLUT4, by 
increasing  the density of GLUT4 in the membrane of the cells (66). The effect of insulin 
in thought to be co-operative, with a Hill constant of about 2 (51;82).  
 
Another possibility for removal of glucose from plasma is the kidneys. Plasma glucose 
can be cleared by the kidneys, however this occur only when the plasma glucose 
concentration is elevated with respect to the normal level, for example in diabetes.  
 
The metabolite lactate is included in the steady state model. There is a small production of 
lactate from the liver, but lactate is mainly produced in muscle and fat cells. In the glucose 
and fat steady state model the majority of lactate is produced from excess glucose. Excess 
glucose is defined as the glucose taken up from plasma which is not utilised through 
glucose oxidation. Through gluconeogenesis, in the liver, lactate is used to produce 
glucose, which is then released back into plasma, completing the glucose-lactate futile 
cycle (the cori cycle). Despite its name, this cycle clearly plays an important role by 
allowing a continuous redistribution of glucose among the various cells and organs.  
 
Another possibility for excess glucose in the cells is de novo lipogenesis (fat synthesis). 
The distribution of surplus glucose between lactate production and de novo lipogenesis is 
determined by the lactate concentration. De novo lipogenesis is considered to occur in the 
liver, in adipose tissue, and to some extent in muscle cells.  
 
The model was named glucose fat steady state model, but in reality it operates with a 
quasi steady state, at least when there is an energy imbalance, when dietary calorie intake 
exceeds or is lower than total energy expenditure. In quasi steady state the insulin level, 
the metabolite levels and the fluxes between metabolites are constant except for adipose 
tissue content. This means that in quasi steady state there can be a net gain or loss of fat 
tissue.   
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2.1.1 Glycogen 
The steady state model is based on the assumption, that over a day there is no net build up 
or break down of glycogen. The body glycogen stores is fairly limited, muscle and hepatic 
glycogen constitutes about 1% of the body’s total energy storages, corresponding to about 
1500-2000 kcal which is less that a days worth of energy (66).  Hence, a longer lasting 
excess or shortage of glucose can not be dealt with through the glycogen storages.   
2.1.2 Glucose Oxidation 
As mentioned above, oxidation is one of the major areas of interplay between the glucose 
and fat metabolism. In the glucose fat steady state model the rate of glucose oxidation is 
determined by the total need for energy (total energy expenditure), and the rate of non-
esterified fatty acid oxidation, ketone body oxidation, and protein oxidation. Both fatty 
acid oxidation and ketone oxidation is regulated by the availability of substrates (64;118). 
However the availability of both fatty acids and ketones is indirectly regulated by insulin.  
2.1.3 The Cori Cycle and De novo Lipogenesis  
A continuous excess of glucose, for example through a high level of carbohydrate in the 
diet, is in the steady state model primarily dealt with by formation of lactate. 
Glyconeogenesis from lactate, the cori cycle, is important in the regulation between 
glucose and fat metabolism in the steady state model. When the glucose uptake into the 
cells, is higher than the need for glucose oxidation, the excess glucose can escape the cells 
through the cori cycle. All cells can produce lactate through glycolysis and, contrary to 
glucose lactate can be transported out of the cells.  Lactate can be taken up by the liver, 
where it is regenerated as glucose and again released into the systemic circulation. In a 
situation of excess energy, the glucose-lactate cycle increases the flow of glucose in the 
system and there by also insulin production. In situations of energy fatigue the cori cycle 
makes the possible for the body to utilise the energy stored as muscle glycogen, in other 
parts of the body. During fatigue the cori cycle can also have an important function in 
maintaining the plasma glucose level. Even though the cori cycle does not contribute to 
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any net glucose production, it makes sure that the glucose taken up by muscle and adipose 
tissue despite the relative low glucose and insulin levels are redirected back into plasma. 
Hyperlactaemia is defined for a lactate concentration between 2 mM and 5 mM, and 
severe lactic acidosis (metabolic acidoses) is said to occur when the lactate concentration 
exceeds 5 mM. So, when excess glucose is too high to be dealt with through the glucose-
lactate cycle, the secondary choice is production of fat, de novo lipogenesis. In the steady 
state model, the lactate concentration regulated the production of fat through lipogenesis.  
The activity of de novo lipogenesis is strongly dependent of the pyruvate and lactate 
concentrations (120). 
2.1.4 Glyconeogenesis 
One of the areas where the glucose and fat steady state model has been modified is 
glyconeogenesis. Gluconeogenesis from lactate is described in the section above, the cori 
cycle. Gluconeogenesis from glycerol is also an important source of glucose, especially 
during fasting or starvation. Glycerol is released when triglycerides are hydrolysed to 
yield 3 fatty acids and one glycerol. This means the glycerol release in proportional to the 
rate of adipose tissue lipolysis and lipoprotein lipase, all is made in to glucose. However 
when fatty acids are re-esterified, the glycerol needed is produced from glucose. Therefore 
the net contribution of glycerol to glyconeogenesis in steady state is considered to be 
proportional to the rates of fat oxidation and ketone body formation, which are end roads 
for fatty acids. Gluconeogenesis from amino acids and glycerol are slower than the rate of 
gluconeogenesis from lactate (84). The rates depend on the concentration of the 
precursors, and half-maximal rates are observed at concentrations that exceed the usual 
plasma concentrations (84), which means the rates are not saturated. The model 
production of glucose from amino acids is considered to be 50% of dietary protein intake, 
the other 50% are considered to be oxidised. 
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2.1.5 Glucose and Fat Steady State Model Equations 
The differential equation representing the change in concentration of the eight metabolites 
(including insulin) described in the steady state model, and the related fluxes between 
metabolites are shown below. All glucose fluxes (including to and from lactate) are in 
mmol glucose/min, one mmol glucose yield two mmol lactate. All lipid fluxes are in µmol 
NEFA/min, including ketone bodies. It takes three µmol NEFA to yield one µmol 
triglyceride, while one µmol NEFA yields 4 µmol ketone bodies. All state variables are 
presented at concentrations. This means that the net change in flux is divided by the 
relevant distribution volume (V). For plasma triglyceride and NEFA the distribution 
volume (VP) is 3 litre (13). For Ketone bodies the distribution volume is higher (VKB) 14 
litre (118). The distribution volume for insulin (VI) is also 14 litre (78). For lactate and 
glucose it is even higher (VL and VG) 17 litre (78). 
 
Plasma chylomicron triglyceride: 
( )C
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Vdt
dTG
⋅−⋅⋅= 3
1
3
11
 
eq. 1 
Plama VLDL triglyceride 
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eq. 2 
Plasma non-esterified fatty acids 
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eq. 3 
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Adipose tissue 
( ) ( ) DNLATRATLLPLLPLLPLsp
dt
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11  
eq. 4 
Plasma ketone bodies 
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Vdt
dKB
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eq. 5 
Plasma glucose 
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eq. 6 
Plasma lactate 
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Vdt
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eq. 7 
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Lipoprotein lipase rates: 
[ ]( )
[ ] [ ]
[ ]
[ ]IK
KI
TGTGK
TGV
LPL
ILPL
I
VLDLCTGLPL
CLPL
C
+
+
⋅
+⋅+
⋅⋅
=
,,
ε
ε
 
eq. 9 
[ ]
[ ] [ ]
[ ]
[ ]IK
KI
TGTGK
TGV
LPL
ILPL
I
VLDLCTGLPL
VLDLLPL
VLDL
+
+
⋅
+⋅+
⋅
=
,,
ε
 
eq. 10 
 
 28
Regulation of lipoprotein lipase spillover into plasma: 
[ ]( )( )spSPsp KIaLPL −⋅+= exp1
1
 
eq. 11 
Adipose tissue lipase rate: 
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eq. 12 
Adipose tissue re-esterification rate: 
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eq. 13 
Fatty acid oxidation rate: 
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+
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eq. 14 
 
Ketone body oxidation rate: 
[ ]
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+
⋅
=  
eq. 15 
Hepatic fatty acid uptake rate: 
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eq. 16 
Insulin stimulation of hepatic re-esterification and VLDL secretion rate: 
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eq. 17 
Ketone body clearance: 
[ ]KBRKBcl KBcl ⋅=  
eq. 18 
Rate of glyconeogenesis from glycerol: 
 ( )( )HFUHFDFOXGNGG ⋅−+⋅= 1CG  
eq. 19 
Rate of glucose transport through GLUT1: 
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Rate of glucose transport through GLUT3: 
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eq. 21 
Rate of glucose transport through GLUT4: 
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eq. 22 
Renal clearance of glucose: 
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Rate of glucose oxidation: 
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Rate of gluconeogenesis from lactate: 
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Hepatic lactate production rate: 
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eq. 26 
Rate of lactate production: 
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Rate of de novo lipogenesis: 
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Insulin secretion rate: 
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Insulin clearance rate: 
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Table 1: Glucose Fat Steady State Model Parameters 
VP 3 L Estimated from (13) 
VKB 14 L Estimated from (118) 
VG 17 L (78) 
VL 17 L  
VI 14 L (78) 
VLPL 1750 µmol/min *Estimated from (3;35;56;96) 
KLPL,TG 200 µM (22;33). 
ε 10   
KLPL,I 200 pM (35;55;65)   
I0 30 pM  
aSP 0.02 pM-1 Estimated from (38) 
KSP 200 pM Estimated from (38) 
VATL 50 µmol/kg fat/min *Estimated from (25;26;35;165) 
KATL 50 µM (17;25;26;40;150) 
BATL 10 µmol/kg fat/min (25;26) 
VRST 150 µmol/kg fat/min *Estimated from (25;164) 
KRST,FA 1500 µM (104) 
KRST,I 200 pM Estimated from (74) 
VFOX 370 µmol /kcal *Estimated from (2;11;113;159) 
KFOX 478 µM *Estimated from (2;11;113;159) 
VHFU 600 µmol /min *Estimated from (80) 
KHFU 1500 µM (80) 
KHFD 25 pM Estimated from (111) 
VKBOX 200 µmol /min (118) 
KKBOX 1000 µM (118) 
RKBcl 0.15 L/min  
CG 0.0005 mmol glucose/ µmol glycerol 
VGLUT1 1.2 mmol/min (78) 
KGLUT1  10 mM (72) 
VGLUT3 0.6 mmol/min *Estimated from (66) 
KGLUT3 1.6 mM (66) 
VGLUT4 7.1 mmol/min *Estimated from (82) 
KGLUT4 5 mM (66) 
KGLUT4,I 180 pM *Estimated from (82) 
α 2  *Estimated from (51;82) 
VGNG,L 2 mmol/min *Estimated from (84) 
KGNG,L 0.5 mM *Estimated from (66;84) 
VHGU 1 mmol/min *Estimated from (84) 
KHGU 0.5 mM *Estimated from (66;84) 
β 4   
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KDNL 2 mM *Estimated from (66;84) 
VSC 2000 pmol/min (78) 
KSC 7.4 mM (78) 
γ 6.4  (78) 
VCL1 1400 pmol/min (78) 
KCL1 2000 pM (78) 
VCL2 2750 pmol/min (78) 
KCL2 5000 pM (78) 
k3 0.18 L/min (78) 
* The estimation is based on the assumption about the mathematical relationship made 
here when describing the flux.  
 
Total energy expenditure EE, and total fat mass is set for each simulation.  
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2.2 GLUCOSE FAT STEADY STATE MODEL SIMULATIONS 
As mentioned the glucose and fat steady state model in used to simulate a hypothetical 
situations where the daily variations in metabolites and hormones (insulin) and the fluxes 
between metabolites are averaged out. Therefore it is difficult to validate the model.  In an 
attempt to validate the model it is used to simulate a study of massive carbohydrate 
overfeeding.  The study and the model simulation of massive carbohydrate overfeeding 
are described in the following section “Massive Carbohydrate Overfeeding”. In the 
section “Simulation of Hyperinsulinaemic Glucose Clamp” the glucose and fat steady 
state model is used to simulate hyperinsulinemic glucose clamp studies. The setup of 
glucose clamp studies is very similar to the setup of the steady state model. In a glucose 
clamp study insulin and glucose concentrations are kept constant, through infusion of 
insulin and/ or glucose. Often, the body’s own production of insulin is set out of function 
through infusion of the drug somatostatin. These simulations are done to show the 
complexity of the regulation of glucose metabolism and the importance in considering 
glucose utilisation and not only glucose uptake into the cell. And further more the 
importance in taking the nutritional condition of the person into account, when evaluation 
results of glucose clamp studies. To further illustrate the importance of including the 
glucose utilisation in the cells when describing the glucose metabolism, a simple model of 
hexokinase was made. The model shows how intercellular glucose inhibits glucose 
uptake, if glucose utilisation within the cells is not stimulated simultaneous to stimulation 
of glucose transport. The mechanism of the regulation of glucose uptake by intercellular 
glucose is not described in the glucose and fat steady state model.     
2.2.1 Massive Carbohydrate Overfeeding 
The model is used to simulate situations of underfeeding (negative energy balance) and of 
massive carbohydrate overfeeding in humans (positive energy balance). In a study by 
Acheson et al (1988), healthy subjects first underwent three days on a low calorie diet, 
consisting of 1600 kcal per day, which is composted of 15% protein, fat and carbohydrate. 
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After three days of low calorie diet, glycogen stores are considered depleted. Therefore 
the subjects will be considered to be in a “steady state”, which is attempted to simulate 
using the glucose and fat steady state model. After the 3 days on a low calorie diet, the 
subjects are massively overfeed with carbohydrates for 10 days. During the 10 days the 
diet consists of an energy surplus of 1500 kcal/day, relative to the energy requirements of 
the subjects. The diet is composed of 11% protein, 3% fat and 86% carbohydrate. At day 
10 of the high kcal high carbohydrate diet the glycogen stores are considered to be 
replenished, and again the subjects can be considered to be in a “steady state (1).  This 
situation is simulated with the glucose fat steady state model. The simulations of the two 
situations are used to see if the model is able to replicate the utilization of the food intake 
during negative and positive energy balance.  
 
One of the values used to evaluate energy expenditure and nutrition oxidation is the non-
protein respiratory coefficient (npRQ). The npRQ are calculated as follows: 
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eq. 31 
 
Where c0 is the rate of carbohydrate oxidation in g glucose/min, f0 is the rate of fat 
oxidation in g fat/min and cf in the rate of de novo lipogenesis in g glucose/min (62). 
 
In figure 3 results of simulation of low calorie high fat diet and high calorie, high 
carbohydrate diet are shown. Model input are dietary protein, fat and glucose intake and 
total energy expenditure in the two situations. These values for total energy expenditure 
and dietary intake are found in the Acheson, et al (1988) study described above. The 
figure shows the experimental found values for energy expenditure and the contribution of 
glucose, fat and protein to total energy expenditure, non protein RQ, total carbohydrate 
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utilization which includes carbohydrate oxidation and de novo lipogenesis, and total 
carbohydrate intake. These value are compared the corresponding simulated values.  
 
For the low calorie, high fat diet the model seems to underestimate fat. Instead the model 
predicts a considerable ketone body oxidation, which is probably included in the 
experimental fat oxidation. For the low calorie, high fat diet the model predicts protein 
oxidation fairly well, but overestimates protein oxidation in the high calorie, high carb 
diet. The model can only include protein metabolism in a very simplified way, where it is 
assumed that all protein provided to the metabolism through meals are utilized, so when 
there is a net storage of protein, as found experimentally for the high kcal, high carb diet, 
the model will not be able to capture this. For the simulation shown in figure 3 the model 
was modified a bit, so the protein provided through the meal is considered fully oxidised 
instead contributing to glucose production through glyconeogenesis, with 50% of protein 
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Figure 3: Glucose-Fat Steady State Model Simulation of Acheson, et al (1988) study with low kcal - high fat 
diet and high kcal - high carbohydrate diet. The steady state simulation fluxes (Sim, low kcal and Sim, high kcal) 
are compared to the fluxes found in the study after three day of low kcal high fat diet (Exp, low kcal) and after 7 
days of high kcal high carbohydrate diet  (day 10 of study) (Exp, high kcal), respectively. GNG from protein is 
set to zero instead all protein provided though the meals is oxidised.  
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provided through meals. This is done since, gluconeogenesis from protein will 
experimentally be considered as protein oxidation, which is measured by the amount of 
nitrogen in the urine. Simulated non-protein RQ corresponds to the non-protein RQ found 
in the study, and both simulation and study finds that the rate of de novo lipogenesis is 
zero.  
 
For the high calorie, high carbohydrate diet the model again under estimate fatty acid 
oxidation while overestimating protein oxidation and glucose oxidation is. As for protein 
oxidation, the simple form in which protein in included in the model does not allow for 
protein storages therefore all protein provided through meals are oxidised. Compared to 
the study the model underestimates non-protein RQ a bit, which can be ascribed to the 
overestimation of glucose oxidation and underestimation of net de novo lipogenesis, see 
figure 3 in the bottom left corner.   
2.2.2 Simulation of Hyperinsulinaemic Glucose Clamp 
The glucose and fat steady state model is used to simulate situations compatible with 
hyperinsulinaemic glucose clamp. The set up of a clamp study is a situation that is close to 
that of the steady state model. During a glucose clamp, insulin and glucose concentrations 
are kept at a constant level, through invervenous infusions of insulin and/ or glucose. 
Figure 4 shows the glucose infusion rate during an 8 hour hyperinsulinemic 
hyperglycaemic clamp study, where glucose was kept with in 20-22 mM and insulin 
concentration was 12000 pM. The study involved two male healthy subjects (76). The 
figure shows how the glucose infusion rate (GIR) decreases with in the duration of the 
study; this decrease is considered to by due to the limitation of glycogen storages 
capacity. The glucose and fat steady state model stimulation of hyperinsulinemic glucose 
clamp will find GIR in a situation where there are no glycogen storages. The glucose and 
fat steady state model predicts a GIR of 4.7 mmol/min which corresponds to around 70 
µmol/kg/min, for at 70 kg person, with plasma glucose concentration of 22 mM and 
insulin concentration of 12000 pM (total energy expenditure was set to 1.66 kcal/min). 
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The steady state rate of glucose infusion needed to keep glucose concentration constant is 
found as follows:  
nesisGluconeogeclearencenaluptakeeGluGIR −+= Recos  
For the simulation model insulin secretion and elimination is set to zero. The GIR found 
in the simulation is about 4 fold lower than the initially experimental GIR and about 2.5 
fold lower than the experimental determined GIR after 8 hours with hyperinsulinemic 
hyperglycaemic glucose clamp (76).  
 
Figure 5 shows a model simulation of a hyperinsulinemic euglycemic clamp. The steady 
state GIR, is found for a glucose concentration of 4.8 mM and a variety of insulin 
concentration from 50 pM to 1000 pM. The glucose infusion rate needed to keep glucose 
constant at 4.8 mM increases with insulin, but saturates at an insulin concentration around 
600 pM, at a rate just below 3 mmol/min. The fate of a majority of the glucose is 
oxidation, however from an insulin concentration around 150 pM the model predicts 
lipogenesis to occur. The rate of glucose oxidation and lipogenesis increases with insulin,  
 
 
Figure 4: Figure tatken from Hansen, B.F, et al (1999). Glucose 
infusion rate (GIR) during an 8 hour hyperinsulinaemic 
hyperglycaemic clamp study, ♦ subject 1 and ○ subject 2. Glucose 
concentration 20-22 mM insulin concentration of 12000 pM (76).  
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but as with GIR the rates saturate for high insulin levels. An experimental 
hyperinsulinemic euglycemic clamp study with glucose 4.8 mM and insulin 360 pM, finds 
GIR to be around 3.9 mmol/min and glucose oxidation to be 1.36 mmol/min (147). The 
glucose and fat steady state model GIR is about 2.2 mmol/min and glucose oxidation 1.6 
mmol/min, for the same glucose and insulin concentrations (model total energy 
expenditure was 1.66 kcal/min). The difference between the experimentally found GIR 
and the model simulated GIR (1.7 mmol/min) could be due to glycogen stores, which (as 
mentioned) are not included in the steady state model.  
 
Alterations in insulin’s regulation of lipid metabolism can influence the results of glucose 
clamp studies, see figure 6. The model regulation of adipose tissue lipase and re-
esterification by insulin was altered by a two fold increase in the Km values for inhibition 
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Figure 5: Glucose and fat steady state model simulation of hyperglycaemic glucose clamp in steady state. 
Insulin in varied from 50 pM to 1000 pM, glucose kept constant at 4.8 mM and 10 mM 
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by insulin of lipase and its stimulation on re-esterification. For lower insulin 
concentrations this resulted in a decrease in GIR, due to decrease in glucose oxidation, 
and failure of insulin to suppress plasma non-esterified fatty acid concentration. The 
simulation show the lower than expected GIR is not necessarily a result of decreased 
insulin effect on glucose metabolism, but can also be explained by decreased inhibition of 
net adipose tissue release of fatty acids to plasma by insulin.  
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Figure 6: Simulation of hyperinsulinimic glucose clamp study with alteration in insulin’s regulation of lipid 
metabolism, glucose is kept constant at 5 mM and steady state is found for insulin concentration varied between 
50 and 1000 pM.  
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2.3 A SMALL MODEL OF HEXOKINASE 
To further illustrate the importance of considering the utilisation of glucose when looking 
at glucose metabolism a small model of hexokinase is constructed, for schematic 
presentation see figure 7. Hexokinase is the enzyme that phosphorylates glucose to 
glucose 6-phosphate in the muscle and fat cells. Hexokinase is inhibited by its product, 
glucose 6-phosphate. The model will illustrate how important it is not only to consider 
stimulation of glucose uptake into the cells but also to stimulate the utilisation of glucose 
with the cells. The rate of hexokinase is described by a Michaelis-Menten function with 
so-called mixed inhibition (155), see eq. 35. The rate of glucose uptake into the cell is also 
described by at Michaelis-Menten function, it is in general believed that the GLUT 
transporter are symmetric (93), see eq. 34.  The rate of removal of glucose 6-phosphate is 
for simplicity considered to be proportional to the glucose 6-phosphate concentration eq. 
36. The parameters A and B represent the relative maximal velocity of glucose transport 
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Figure 7: Schematic presentation of 
hexokinase model. The red line illustrates 
the product inhibition of hexokinase by 
glucose 6-phosphate. 
 
Figure 8: The relative flux through the glucose transporter 
for increasing intercellular glucose.  
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and glucose 6-phosphate utilisation to maximal hexokinase rate, respectively. When A 
increases is represent a stimulation of glucose transport for example by insulin, and when 
B increase it represent a stimulation of glucose 6-phosphate utilisation.  
2.3.1 Simple Hexokinase Model Equations 
( )HKGLUT
Vdt
dGi
−=
1
 
eq. 32 
( )GUHK
Vdt
PdG
−=
16
 
eq. 33 
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eq. 35 
 
PGBGU 6*=  
eq. 36 
 
The model consists of two differential equations, one representing intercellular glucose 
(Gi), and one intercellular glucose 6-phophate (G6P). G stands for plasma glucose 
concentration, GLUT is the rate of transport into the cell, HK is the rate of hexokinase and 
GU is the rate of glucose 6-phoshate utilisation. Parameter values are shown in table 2, for 
graphical illustration see figure 7.  
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Table 2: Parameter values for hexokinase model 
KG 5 mM Estimated from (66) 
KHK 0.188 mM (155) 
KG6P 0.068 mM (155) 
KG6P* 0.022 mM (155) 
 
 43
2.3.2 Simulation with the Simple Hexokinase Model 
If only glucose uptake into the cell is stimulated with out stimulating the rate of glucose 
utilisation within the cell there will be an accumulation of glucose 6-phosphate which 
inhibits hexokinase and thereby also an accumulation of intercellular glucose. This is 
illustrated in figure 9. The effect of increasing intercellular glucose is an inhibition of the 
glucose transport into the cell, see figure 8.  When the utilisation of glucose 6-phosphate 
is also stimulated, the accumulation of metabolites does not happen, and the glucose 
uptake increases with increases stimulation (increasing A). The relative flux is shown in 
figure 9 in the top right corner.  
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Figure 9: The two left plots show the relation between intercellular glucose (in the top) and glucose 6-phosphate 
(in the bottom) and the parameter A for different values of the parameter B. The two right plots shows the 
inhibition of glucose uptake as a function of the parameter A for different values of B.  
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2.4 DISCUSSION OF GLUCOSE FAT STEADY STATE MODEL 
The glucose fat steady state model describes a hypothetical situation where all metabolic 
fluxes and metabolite concentrations are averaged over the day. The model does not 
represent dynamical changes in metabolites over the day, but relations between fluxes and 
metabolites for different nutritional situations. The model was sought validated through 
simulation of an underfeeding study and an overfeeding study. In the simulation of the 
underfeeding study (negative energy balance) the model result resembled those observed 
experimentally. The results of the overfeeding simulation were not similar good. Glucose 
oxidation was overestimated and the rate of fatty acid oxidation and lipogenesis was 
underestimated.  
 
Although the model predicts the utilization of the metabolites at least during the 
underfeeding simulation fairly well, it is difficult to say whether the metabolite 
concentration corresponds to the physiological averages. However the saturating rates of 
Michaelis-Menten functions, by which most of the metabolic fluxes are described, will in 
general overestimate the average metabolic fluxes.  
 
The simulation of hyperinsulinemic glucose clamp shows how important it is to consider 
the not only the uptake of glucose into the cells as being regulated by insulin, but also the 
possible routs of glucose utilisation and there regulation.  Especially the first example 
with the hyperinsulinemic hyperglycemic clamp shows, how decreased GIR might not be 
a symptom of insulin resistance but merely a result of the nutritional state of the 
metabolism. For example the difference between having depleted glycogen depots or only 
having partly depleted glycogen stores.    
 
To further illustrate that it is not enough to consider the transport of glucose into the cells 
but also the utilisation of glucose within the cells, a simple model of hexokinase was 
made. The hexokinase model captures an effect which is not described in the glucose fat 
steady state model. The concentration of glucose inside the cells will inhibit the rate of 
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glucose uptake into the cells. The model shows how an accumulation of intercellular 
glucose occur if utilisation of glucose 6-phosphate in the cell is not stimulated when 
glucose uptake is stimulated. The result of this is decreased glucose uptake. If decreased 
glucose uptake is observed in relation insulin concentration, it is considered to be due to 
insulin resistance, which might by the case. But it is not necessarily the stimulation of the 
insulin dependent glucose transporter that is responsible for the observed insulin 
resistance. In could for example by related the level of glycogen in the cells, if glycogen 
storage is close to its maximal capacity it could influence the rate of glycogen synthesis a 
path for glucose utilisation within the cells. The next section will focus more on the 
mechanisms of glycogen formation and breakdown. Another possibility for decreased 
glucose utilisation could be changes in the fat metabolism. In the simulation of 
hyperinsulinemic glucose clamp, alterations were made in insulin’s ability to suppress 
adipose tissue lipase and stimulate adipose tissue re-estrification. The results show 
decreased glucose oxidation for lower insulin concentration compared to the normal 
regulation capacity of insulin.  
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3 HEPATIC GLUCOSE METABOLISM 
As mentioned in the section “The Interplay between Glucose and Fat” a route of glucose 
utilisation is to be stored as glycogen, and this happens in part in the liver. After a meal, 
nutritions that enter the body form the intestine, reach the liver first.  The liver acts as a 
buffer, taking up glucose when concentration outside is high and releasing glucose when it 
is required elsewhere in the body. During fasting most of the body’s energy requirements 
are meet by fatty acids oxidation and to some extent also protein oxidation. However a 
portion of the energy requirement, about 20% (66) comes from glucose oxidation, and 
during fasting the liver releases glucose in to circulation to prevent hypoglycaemia. After 
an overnight fast, the hepatic glucose output is about 10 µmol/kg/min (161), where about 
50% comes from gluconeogenesis and 50% from glucogenolysis (161). In the 
postabsorptive fase (often refered to as basal state) plasma glucose concentrations are 
about 5 mM and plasma insulin about 40 pM (66). 
 
In this section a physiological model of hepatic glucose metabolism will be described. 
Earlier attempts to construct  a physiological model of hepatic glucose metabolism have 
been made Bergman et al. (8;52). This earlier model was validated by simulating the 
overnight fasting state and comparing intracellular metabolite concentrations with 
measured concentration.  For the simulation, a fasting glucose concentration of 5.55 mM, 
hepatic glycogen content of 242 µmol/g liver and a gluconeogenesis rate of 0.1 µmol/g 
liver/min, were used. However the simulated rates of hepatic glucose output, glycogen 
Table 3: Metabolite concentrations and fluxes from simulation of overnight fast hepatic glucose metabolism 
with Bergman model (8;52) – gluconeogenesis rate 0.1 µmol/g liver/min, compared to measured values 
Overnight fast  Bergman model (52) Measured values for human liver 
Glucose 6-phosphate 0.13 mM 0.2 - 0.4 mM (54) 
UDP-glucose 0.35 mM 0.43 - 0.82 mM (54) 
Hepatic glucose output 0.31 µmol/g liver/min 0.46 - 0.53 µmol/g liver/min (45;81;161) 
Glycogen synthesis 0.58 µmol/g liver/min 0 - 0.12 µmol/g liver/min (81;122) 
Glycogenolysis 0.79 µmol/g liver/min 0.5 - 0.25 µmol/g liver/min (81;122) 
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synthesis and glycogenolysis do not fit with measured rates for healthy humans, see table 
3. The rate of net hepatic glucose output is close to the measured rate, especially taking 
into account that the gluconeogenesis rate is only 0.1 µmol/g liver/min. In the healthy 
human it is considered to be around 0.23 µmol/g liver/min after an overnight fast (161). 
However, the simulated rates of glycogen synthesis and glycogenolysis are several times 
higher than the measured rates. The Bergman model was used to investigate mechanisms 
involved in the regulation of hepatic glucose metabolism in response to increased glucose 
and insulin concentrations.  
 
The model of hepatic glucose metabolism described here will take regulatory effect of 
glucose on hepatic glycogen synthesis and breakdown into account and incorporate them 
in the model. The model is used to investigate mechanisms relevant for the regulation of 
hepatic glucose metabolism by glucose and glycogen. 
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3.1 HEPATIC GLUCOSE METABOLISM MODEL 
The mechanistic model of hepatic glucose metabolism is presented in figure 10. Glucose 
enters the liver primarily through the glucose transporter GLUT2. GLUT2 has a high half 
maximum velocity concentration (Km) and a high maximal rate which allows glucose to 
“equilibrate” across the membrane (66). The GLUT2 transporter is not responsive to 
insulin (66). The low affinity towards glucose and the high capacity for GLUT2, results in 
glucose concentration in the liver is very close to glucose concentration outside. Inside the 
liver cell glucose is phosphorylated by glucokinase to glucose 6-phosphate. In the liver, 
contrary to other tissues, glucose 6-phosphate can be dephosphorylated back to glucose 
though glucose 6-phosphatase. The pathway of glycogen synthesis and breakdown goes 
through glucose 1-phosphate. Glucose 6-phosphate and glucose 1-phosphate are assumed 
to be in rapid equilibrium, due to the high activity of phosphoglucomutase in the liver 
(149), and will be considered to equilibrate instantly. Therefore, the liver glucose 1-
phosphate will not be included in the model. Total liver volume is found to be around 1.5 l 
(32;135). Liver mass is considered to be 1500 g (61;66;135). 
 
Figure 10: Schematic presentation of hepatic glucose metabolism. The thick lines represent fluxes and the 
thin lines represent regulation of flux by metabolite ( + stimulation, - inhibition).  
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3.1.1 Glucokinase 
Glucose entering the liver cell is phosphorylated to glucose 6-phsophate in order to be 
utilized in the liver cells (as for any other cell); in the liver cell it is the enzyme 
glucokinase that catalyzes the glucose phosphorylation. The rate of gucokinase (or 
hexokinase D) in relation to glucose concentration follows a sigmoid curve 
(42;105;124;160).  Glucokinase differs kinetically form the other hexokinases by virtue of 
its cooperative glucose dependence (42;105;124;160), low affinity for glucose Km 7-8 
mM (105;124)  and lack of product inhibition by glucose 6-phosphate (42;105;124). 
These kinetic properties allow glucokinase to respond quickly to changes in glucose 
concentrations under physiological conditions.  
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Figure 11: Rate of Glucokinase in the liver as a function of 
glucose concentration (line). The dots are data points of hepatic 
glucose phosphorylation vs glucose concentration in fasted rats 
(167).   
 
 
 
 
The glucose concentration for half maximal velocity, Km, equals 7.8 mM (124), and the 
Hill coefficient h equals 1.7 (105;124). The maximal velocity, Vmax , is found  to be 1.8 
µmol/g liver/min, by fitting the Hill function to experimental data of hepatic glucose 
phosphorylation versus glucose concentration in fasted rats (167), see figure 11. In in vitro 
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studies with rats, Vmax for flucokinase was found to 1.46 µmol/g liver/min (8;94). The 
mathematical function describing the flux through glucokinase is as follows: 
 
[ ]
[ ]αα
α
GK
GVGK
KG
GK
+
⋅
=  
eq. 37 
 
The enzymes affinity for MgATP (S50 0.3-0.4 mM), its other substrate, is well below the 
intracellular concentration of MgATP (~2.5 mM). This assured that the metabolic flux 
depends almost entirely on the concentration of glucose and the amount of glucokinase 
within the cell (105).  
3.1.2 Glucose-6-phosphatase 
The Km of Glucose 6-phosphatase is 2-3 mM, which is higher than the intracellular 
concentration of glucose 6-phoshate considered to be between 0.05 and  1 mM 
(54;54;84;158)  in the liver. The inhibition exerted by glucose on G6Pase is probably of 
little physiological significance, since the half maximal suppression constant (Ki ~ 0.1 M) 
is more than one order of magnitude above glycemia (158). The controle of glucose 6-
phosphatase activity therefore appears simple since it does not involve factors other than 
Vmax and Km, and the substrate concentration. The function describing the flux through 
glucose 6-phosphatase is shown below. 
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[ ]PGK
PGVGPase
GPase
GPase
6
6
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=  
eq. 38 
 
In the fed state, Vmax is close to 10 µmol/g liver/min (83).This value is doubled during 
starvation and diabetes (83). In fasted state (overnight fast) Vmax for glucose 6-phosphatase 
is found to be 13 µmol/g liver/min (94) and 12.3 µmol/g liver/min (142) in rats. This 
agrees with basal Glucose 6-phosphatase rate based on total hepatic glucose output of 0.53 
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umol/g liver/min (45), with a fasting glucose 6-phoshate concentration of 0.2 mM (54) 
and a Km of glucose 6-phophatase of 2 mM (84) and glucose phosphorylation/ 
dephosphorylation recycling of about 50%.  The glucose/glucose 6-phosphate cycle is 
found to be 20-50% in normally fed rats (83). As glucokinase glucose 6-phosphatase is 
not directly regulated in short term by hormonal signals. However, over a matter of some 
hours by changes in enzyme amount (66).  
3.1.3 Glycogen phosphorylase 
Glycogen phosphorylase is the rate determining step in the breakdown of glycogen to 
glucose 6-phosphate (103). Glycogen phosphorylase in regulated by its substrate, by 
glycogen and by orthophosphate (103). In the normal fasted human liver the 
orthophosphate concentration is about 1.4 mM (14), and her it will be considered to 
remain constant at this level. The Km for glycogen is low compared with the overnight 
fasted glycogen concentration of about 250 mM. For glycogen concentrations above 50 
 
 
Figure 12: Correlation between net glycogenolysis and 
hepatic glycogen concentration, from (106). The Rothman 
data are mean net glycogenolysis during-22 hours fast – 
glycogen concentration after 15 hours fast, glucose 
concentration 4.6 mM, insulin 66 pM. Magnusson data 
shows net glycogenolysis and hepatic glycogen content 
after 4, 13.5, 17, 19.5 and 22.5 hours fast, for both healthy 
and diabetic subjects.   
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mM the glycogen phosphorylation rate is more or less constant. However, there are 
several studies that suggest the net glycogenolysis decreases with glycogen concentration 
in a linear fashion  (107;135). This indicate that the glycogen concentration may regulate 
its rate of breakdown and that liver glycogen turnover may be an important factor in 
limiting the accumulation of liver glycogen in humans (106;161), see figure 12.  
 
The decreasing net glycogneolysis with decreasing glycogen concentration, could be due 
to either inhibition of glycogen synthase by glycogen (77) or stimulation of glycogen 
phosphorylase by glycogen (106;161), or a combination of both. However in the 
description of glycogen phosphorylase in is assumed that glycogen stimulates its own 
breakdown. In the section “Simulation of Hepatic glucose production” this will be 
discussed further.  
 
Hepatic glucose metabolism was studied by Hellerstein, et al. (81)  after 11 hours fast and 
after 60 hour fast.  Net glycogenolysis decreased from 0.24 µmol/g liver/min to close to 
zero between 11 and 60 hours fast. Total glycogen phosphorylase decreased from 0.36 
µmol/g liver/min to 0.09 µmol/g liver/min, during the 11 hour and the 60 hour fast, 
respectively. At the same time glycogen syntesis flux decreased from 0.12 µmol/g 
liver/min to 0.09 µmol/g liver/min (81). This drastic decrease in glycogen phosphorylase 
occurs despite that, after 60 hours fast it would be expected that glucagon concentration is 
increased and glucose concentration decreased a bit, both favouring increased glycogen 
phosphorylase activity. This could indicate that glucogen phosphorylase flux decreases 
with glycogen concentration. Hepatic glycogen content is between 185 – 444 mM (50-120 
g) (66), after an overnight fast (12-15 hours fast).  In healthy subjects hepatic glycogen 
content is 251 mM (135), 230 mM (between 191-288 mM) (122).   
 
Glycogen phosphorylase activity is regulated through phosphorylation and de-
phosphorylastion of the enzyme. Glycogen phosphorylase is active in its de-
phosphorylated form (glycogen phosphorylase a) (7).  
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Glucose is a major regulator of human glycogen phophorylase, while UDP-glucose, 
glucose 6-phophate and fructose 1-phosphate are only minor inhibitors of the enzyme in 
human liver (54). Moreover glucose is the only of these for which the concentration 
changes greatly in vivo (54). Glucose inhibit glycogen phosphorylase, by reducing the 
amount of glycogen phosphorylase a (16;54), which is the active from in the liver, and by 
increasing the Km for orthophosphate (54). In the absence of glucose, Km for 
orthophosphate for glycogen phosphorylase a was measured to be 5 mM in human liver. 
At a glucose concentration of 8 mM it was found to be 10 mM (54).  The activity of 
glycogen phophorylase decreased with increasing glucose concentration, at a glucose 
concentration of 8 mM the activity of phosphorylase was 31% of its activity with no 
glucose present. The activity fell to 10% at a glucose concentration of 20 mM (54). Both 
measured at an orthophosphate concentration of 1 mM which is close to the fasting human 
hepatic level of 1.4 mM. The maximal rate of glucogen phorylase with no glycogen 
present and an orthophosphate concentration of 1 mM was 1.3 µmol/ g liver/min (54).  In 
figure 13 (left) the inhibition of glycogen phosphorylase activity enforced by glucose is 
shown. Figure 13 (right) shows the rate of glycogen phosphorylase as a function of 
glucose concentration.  
 
Glycogen phosphorylase flux has been measured during glucose clamps after an overnight 
fast. In the basal state glucose 5 mM and insulin 40 pM, glycogen phosphorylase flux was 
found to be 0.25 µmol/g liver/min (122), no glycogen cyling was found. The net glycogen 
phosphorylase flux of 0.25 µmol/g liver/min, fits with net glycogen phophorylase found 
0.24 µmol/g liver/min after an overnight fast (81), mentioned above. However here 
glycogen cycling was 33 %, corresponding to a glycogen synthesis of 0.12 µmol/g 
liver/min and total glycogen phosphorylase of 0.36 µmol/g liver/min. At a plasma glucose 
concentration clamped at 10 mM and with insulin kept at 40 pM, the glycogen 
phosphorylase rate was measured to be 0.05 µmol/g liver/min (122), again after an 
overnight fast.  Glycogen phosphorylase is stimulated by glycagon (7;16). This accounts 
 54
for the higher rate of glycogen phosphorylase at a glucose concentration of 10 mM 
determined by the relation showed in figure 13 (right) compared to the data from Petersen 
et al. (122). This data is also plotted in figure 13.  This study also showed a 25% increase 
in glycogen phosphorylase rate at basal glucose (5 mM) and insulin (40 pM) 
concentrations with "high" 50 ng/l glycogen concentration compeared to at "low" 30 ng/l 
glycogen concentration. Regulation of glycogen phosphorylase by glucagon is not 
included in the model.  
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Figure 13: To the left – Effect of glucose on the relativ activity of human liver glycogen phosphorylase. The 
relationship can be described by a Mmichaelis-Mmenten type function; half maximal activity is at a glucose 
concentration of 3.2 mM. To the right – Rate of glycogen phosphorylase as a function of glucose. Hepatic 
orthophosphate concentration is 1.4 mM, hepatic glycogen concentration 250 mM. 
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eq. 39 
 
The function describing the rate of glycogen breakdown is shown above. As mentioned, 
the rate of glycogen breakdown is stimulated by is products orthophosphate and glycogen. 
 55
This relation is described by a Michaelis-Menten like function (103). Glucose lowers the 
affinity of glycogen phophorylase to orthophosphate and, at the same time, it increases the 
maximal velocity. The glucose stimulation of glycogen phosphorylase is also decribed by 
a Michaelis-Menten type function. Furthermore, glycogen also increases the rate of 
glycogen breakdown, this effect is described in a linear manner.  Parameter values are 
shown in  
table 4.  
3.1.4 Glycogen synthesis 
Glycogen synthase catalyses the rate-determining reaction in glycogen synthesis (148). 
Glycogen synthase is stimulated indirectly by glucose, on several levels. As for glycogen 
phoshorylase, glycogen synthase is regulated though phosphorylation and de-
phophorylation of the enzyme, glycogen synthase is active in its phosphorylated form (7). 
 
Glucose increases hepatic glucose 6-phosphate, which stimulates glycogen synthase 
activity and increases the affinity for its substrate UDP-glucose. As mention in an earlier 
section, glucose inhibits glycogen phosphorylase activity which results in increased 
glycogen synthase activity, through decreased inhibition of glycogen synthase by 
glycogen phosphorylase (16). Here glucose concentration is used as a stimulator of 
glycogen synthesis, due to the very complex indirect effect of glucose.  
 
Glycogen synthesis rate at glucose concentrations of 5 mM is found to vanish (122). 
However, another study reports glycogen synthesis rates of 12 µmol/g liver/min in the 
overnight fasted state and a glycogen cycling  of 33% (81), after an overnight fast.  At 
glucose concentrations of 10 mM, the glycogen synthesis rate was found to be 0.05 
umol/g liver/min (122), with a glycogen cycling of 100% (45;122). Glycogen synthesis 
rate is described by a Michaelis-Menten function. The model is simplified so that the 
glycogen synthesis flux depends on the hepatic glucose 6-phosphate concentration and 
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that the maximal velocity in enhanced in a linear way by glucose. The function is given 
by: 
[ ] [ ]
[ ]PGK
PGV
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GGgS
GgS
GgS
GGgS 6
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⋅=  
eq. 40 
Model parameter values are shown in  
table 4. 
3.1.5 Gluconeogenesis 
It is widely believed that glucogenolysis and gluconeogenesis each contribute 
approximately 50% of glucose turnover in healthy subjects after an overnight fast (161), 
this gives a gluconeogenesis rate of about 0.23 µmol/g liver/min (~ 5 µmol/kg/min), 
corresponding to a total glucose output of 0.47 µmol/g liver/min (161).   
3.1.6 Hepatic Glucose Metabolism Model Equations 
In this section all differential equations and model fluxes are collected. Below are first the 
two differential equations, representing hepatic glucose 6-phosphate and hepatic 
glycogen:  
[ ] ( )GgPGgSNEOGPaseGK
Vdt
PGd
+−+−⋅=
16
 
eq. 41 
[ ] ( )GgPGgS
Vdt
Ggd
−⋅=
1
 
eq. 42 
 
Herafter follow the four earlier described functions for Hepatic Glucose Metabolism 
Model flux shown, followed again by the parameters of  the Hepatic Glucose Metabolism 
Model: 
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eq. 39 
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Table 4: Hepatic Glucose Metabolism Model Parameters 
V 1.5 L (32;135) 
VGK 1.8 µmol/g liver/min Estimated from (167).   
KGK 7.8 mM (124) 
α 1.7  (105;124) 
VGPase 13 µmol/g liver/min  
KGPase 2 mM (84) 
VGgS 0.122 µmol/g liver/min Estimated from glycogen synthase rate (81;122). 
KGgS 0.2 mM (92) 
KGgS,G 4.2 mM Estimated from glycogen synthase rate (81;122). 
VGgP 5.5 µmol/g liver/min Estimated from overnight fast glycogenolysis rate 
(81;122). 
K4 0.92 mM (103) 
K1 13 mM (103) 
KPi 5 mM (54)  
KPi,G 8 mM (54)  
KGg 250 mM Estimated overnight fast glycogen content (135) 
KGgP,G 3.2 mM (54) 
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3.2 SIMULATION OF HEPATIC GLUCOSE PRODUCTION  
Through simulations with the hepatic glucose model the mechanisms described in the 
above section are evaluated, and the mechanism by which glucose regulates its own 
production is investigated.  In the model of hepatic glucose production, the activity of 
glycogen synthase is indirectly stimulated by glucose, and glycogen phosphorylase is 
inhibited directly both allosteric and through regulation of activity.  The apparent 
regulation of net glycogen formation/breakdown by glycogen itself is also explored 
further. Data suggests that net glycogenolysis decreases with decreasing glycogen 
concentration, see figure 12 (106). And, in muscle it was found that glycogen 
concentration suppresses net glycogen synthesis (77).  In the hepatic glucose metabolism 
model, the regulation of glycogen formation/breakdown is through glycogen stimulation 
of glycogen phosphorylase. However, it has also been suggested that the mechanism for 
this regulation is through glycogen inhibition of glycogen synthasis (77). This will be 
investigated further in this section.   
   
3.2.1 Glucose regulation of hepatic glucose metabolism 
The model is used to explore four different situations regarding the mechanism by which 
glucose regulates its own production. First the effect of mass action, where there are no 
indirect stimulation of glycogen synthase by glucose neither any inhibition of glycogen 
phosphorylase activity by glucose. In a second situation the glucose stimulation of 
glycogen synthase is present. The third situation only has the glucose inhibition of 
glycogen phosphorylase by not the stimulation of glycogen synthase. And the last 
situation has both glucose stimulation of glycogen synthase and glucose inhibition of 
glycogen phosphorylase.  
 
For all situations the relevant model version is used to determine quasi steady state for 
glucose concentrations between 4 and 17 mM. It is quasi steady state since the glycogen 
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concentration is not constant.  The rate of gluconeogenesis is constant for all simulation at 
0.265 µmol/g liver/min. The hepatic glucose output found through the simulations is 
compared to measured hepatic glucose output (45), during a 3-step hyperglycaemic 
glucose clamp, see figure 14. The data used are from young as well as older healthy 
subjects, normal BMI, mean age was 25 years and 59 years, respectively. During the 
clamp study, insulin and glucagon concentrations were kept at overnight fasting levels. 
Insulin concentration was 84 pM and glucagon 102 ng/l for young subjects and 72 pM and 
173 ng/l in older subjects.  
 
From the simulation using the model version where only the mass action of glucose 
regulates hepatic glucose output (see figure 14 upper left corner), it is obvious the mass 
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Figure 14: Hepatic glucose metabolism model simulation of hepatic glucose ouput, compared to hepatic 
glucose output measured during a 3 step glucose clamp where insulin and glycagon is kept at basal level. The 
figure shows simulations with four version of the hepatic glucose model.   
 60
action alone can not ensure the regulation of hepatic glucose production by glucose. The 
rates of glycogenesis and glycogenolysis are shown in figure 15. 
 
 In the second model version used (simulation is showed in the upper right corner of 
figure 14) glucose stimulates the activity of glycogen synthase. This mechanism alone 
gives some decrease of hepatic glucose output, altthough not enough to explain the 
relation between plasma glucose concentration and hepatic glucose output observed in the 
data. However, if the effect of glucose in glycogen synthase is increased two fold, 
relatively to the parameter values given in  
table 4, the observed hepatic glucose output in relation to glucose concentration can be 
explained only by mass action and glucose stimulation of glycogen synthesis (simulation 
not shown). However, since glucose stimulation of glycogen synthasis is indirect and in 
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Figure 15: Four version of the hepatic glucose metabolism model simulating hepatic glucose output in quasi 
steady state as a function of glucose concentrations. The figures show glucogenesis and glycogenolysis rates.  
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part regulated through the inhibitory effect of glucose on glycogen phosphorylase, it does 
not seem reasonable that without the down regulation in phoshorylase the indirect 
glycogen synthase stimulation is two fold higher that with down regulation of 
phosphorylase. 
 
Like with, the model version where the effect of glucose on hepatic glucose metabolism is 
through mass action and through glucose inhibition of the activity of glycogen 
phosphorylase and allosteric regulation the enzyme, is not able to explain the observed 
down regulation of hepatic glucose output with increasing glucose concentration. It is 
especially for high glucose concentrations (above 10 mM) that the glucose inhibition of 
glycogen phosphorylase fails to explain the observed relation between glucose 
concentration and hepatic glucose output. Increasing the inhibition effect of glucose will 
not be able to explain the rate of hepatic glucose output for the high glucose 
concentration, since glycogenolysis flux will have to be negative in order to reach the 
hepatic glucose output experimentally observed at a glucose concentration around 16 mM 
(see figure 15 - bottom left).   
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When both the glucose stimulation of glycogen synthase and the glucose inhibition of 
glycogenolysis is taken in to account (this corresponds to the model defined in section 
“Hepatic Glucose Metabolism Model Equations”) the model is able to reproduce the 
relation between hepatic glucose output and plasma glucose concentration observed in the 
3 step hyperglycaemic clamp study (45), see figure 14 - bottom left. The rates of glycogen 
synthesis and glycogenolysis are shown in the lower right corner of figure 15, and the 
variation of the glucose 6-phosphate concentration with glucose concentration in figure 
16. The simulated glucose 6-phosphate concentration is within the physiological range in 
the human liver, which is between  0.05 and  1 mM (54;54;84;158).  
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Figure 16: Simulated glucose 6-phosphate concentration 
from quasi steady state of hepatic glucose output simulation 
using the model defined in section “Hepatic Glucose 
Metabolism Model Equations”. Including both glucose 
effects on glycogen synthase and glycogen phosphorylase. 
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3.2.2 Glycogen regulation of hepatic glucose metabolim 
To investigate glycogen regulation of hepatic glucose metabolism, two possible 
mechanisms are described; A mechanism where glycogen stimulates its own breakdown 
and a mechanism where glycogen inhibits its own synthesis. The model is used to see if 
either of the two mechanism can explain the experimentally observed decreases in 
glycogen synthesis with increasing glycogen content (76) and the decrease in glycogen 
breakdown with decreasing glycogen levels (106).  
 
In figure 17 and figure 18 the hepatic glucose metabolism as described in “Hepatic 
Glucose Metabolism Model Equations” is used to simulate hepatic glucose output for 24 
hours with a constant glucose concentration of 5 mM and initial glycogen concentration of 
250 mM (figure 17) and with a constant glucose concentration of 15 mM and initial 
glycogen concentration of 250 mM (figure 18 ).  Both in the situation of net 
glycogenolysis (plasma glucose 5 mM) and in the situation of net glycogenesis (plasma 
glucose 15 mM) the hepatic glucose metabolism model where glycogen regulates its own 
breakdown shows a linear correlation between glycogen content and net glycogenolysis 
and net glycogenesis, respectively. This corresponds to the experimentally observed linear 
relation between glycogen breakdown/synthesis and glycogen (77;106). 
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Figure 17: Simulation of hepatic glucose output, net glycogenolysis for 24 hours with initial glucogen 
concentration at 250 mM and constant plasma glucose concentration of 5 mM. 
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Figure 18: Simulation of hepatic glucose output, net glycogen synthesis for 24 hours with initial glucogen 
concentration at 250 mM and constant plasma glucose concentration of 15 mM. 
 
In the literature it has been suggested that the glycogen inhibits its own synthesis through 
a mechanism related to the binding of both glycogen synthase and glycogen phosphatase 
to glycogen as part of a glycogen protein complex, which also includes glycogen 
phoshorylase (77). Glycogen phosphatase is the enzyme involved in the 
dephosphorylation of glycogen synthase to its active form (7). To see if a similar result 
could be obtained were glycogen, instead of stimulating its own breakdown, inhibits its 
own synthesis the model is modified so that, the function describing glycogen synthesis 
eq. 40 is modified to read: 
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and the function describing glycogen phosphorylase flux eq. 39 is modified to become:  
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The parameters are the same as stated in table 4. The inhibition of glycogen synthase by 
glycogen is constructed so that at overnight fasted glycogen level (250 mM) the glycogen 
synthesis rate is not inhibited, and for zero glycogen the rate in 6.5 fold higher. This is 
done since the maximal rate of glycogen syntase (VGgS) is estimated based on the 
overnight fasted glycogen synthesis rate.  
 
The modified hepatic glucose metabolism model is used to simulate hepatic glucose 
output for 24 hours with a constant glucose concentration of 5 mM and initial glycogen 
concentration of 250 mM (figure 19) and with a constant glucose concentration of 15 mM 
and initial glycogen concentration of 250 mM (figure 20). According to the simulation 
with the modified hepatic glucose metabolism model also a mechanism where glycogen 
inhibits its own synthesis can also explain the linear relationship between net 
glycogenolysis and glycogen content, as well as between net glycogen synthesis and 
glycogen levels as observed experimentally (77;106).   
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Figure 19: Simulation with modified hepatic glucose metabolism model of hepatic glucose output, net 
glycogenolysis for 24 hours with initial glucogen concentration at 250 mM and constant plasma glucose 
concentration of 5 mM. 
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Figure 20: Simulation with modified hepatic glucose metabolism model of hepatic glucose output, net 
glycogenolysis for 24 hours with initial glucogen concentration at 250 mM and constant plasma glucose 
concentration of 15 mM. 
 
In the situation where there is a net glycogenolysis (plasma glucose 5 mM) there no 
significant change in the relation of net glycogen breakdown and glycogen, between 
glycogen stimulation of glycogen breakdown and glycogen inhibition of glycogen 
synthesis.  
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3.3 DISCUSSION AND CRITIQUE OF THE HEPATIC GLUCOSE METABOLISM MODEL 
The role of the liver in maintaining plasma glucose levels during fasting and its 
contribution to glucose homeostasis in the postprandial state is considerable. The hepatic 
glucose metabolism model presented here focus on the regulation of hepatic glucose 
metabolism by glycogen and glucose. The model is able to predict hepatic glucose output 
in relation to the plasma glucose concentration, which is compatible with the 
experimentally observed hepatic glucose output found during a three-step hyperglycaemic 
glucose clamp study where glucagon and insulin were kept at basal level (45). It was 
found that both stimulation of glycogen synthase by glucose and inhibition of glycogen 
phosphorylaser by glucose were necessary in order to explain the relation between hepatic 
glucose output and plasma glucose concentration experimentally observed (45). 
 
The hepatic glucose metabolism model was also used to test if glycogen stimulation of 
glycogen breakdown or glycogen inhibition of glycogen synthesis could explain the linear 
relation between net glycogenolysis and glycogen content experimentally observed 
(77;106). It was found that both mechanisms could explain the linear relationship 
observed. And, of course, it could also be combination of both. The literature provides a 
suggestion as to how the mechanism of glycogen inhibition of it own synthesis could 
work, although it is only speculative (77). The idea is that glycogen binds to both 
glycogen synthase and glycogen phosphatise as part of a glycogen protein complex, which 
also include glycogen phoshorylase (77). How a mechanism for glycogen stimulation of 
its own breakdown works, is not known. However if glycogen in some way increases the 
activity of glycogen phosphorylase, then glycogen synthase activity will also be inhibited 
through the inhibitory effect of glycogen phosphorylase.  
 
The stimulation of glycogen syntase by glucose in reality executed through allosteric 
regulation of glycogen synthase by glucose 6-phosphate and upregulation of active 
glycogen synthase through downregulation of active glycogen phosphorylase. However in 
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the hepatic glucose metabolism model described here, these mechanisms are grossly 
simplified, and the stimulation of glycogen synthase is directly regulated by the glucose 
concentration. Since this mechanism is important for the ability of the liver to regulate its 
glucose metabolism, further work should examine the indirect effect of glucose on 
glycogen synthesis more thoroughly.  
 
The relation describing the mechanism for glycogen inhibition of its own synthesis is a 
linear function and so is the function describing the mechanism for glycogen stimulation 
of its own breakdown. It might be more realistic to describe the two mechanisms through 
a saturated function of michaelis-menten type. It could also be interesting investigate if a 
combination of glycogen stimulation of glycogen phosphorylase and inhibition of 
glycogen synthase can explain the experimentally observed relation between net glycogen 
synthesis/breakdown and glycogen.  
 
In the hepatic glucose metabolism model the rate of gluconeogenesis is considered to be 
constant, and not to be influenced by glucose. However there is some evidence that 
glucose regulates the rate of glyconeogenesis (84).   
3.3.1 Effect of Insulin on the Hepatic Glucose Metabolism 
The hepatic glucose metabolism is also regulated by hormones. The dynamical response 
to plasma and portal insulin concentration is an obvious next step in further development 
of the hepatic glucose metabolism model. Within the time frame of the present study some 
preliminary investigations were made to quantify the effect of insulin on the hepatic 
glucose flux. 
 
Glycogen phosphorylase is regulated by insulin and glucagon (16). Glucogenolysis flux 
was measured during hyperinsulima glucose clamp with a plasma glucose was 5 mM. At 
basal insulin concentrations (40 pM), glycogenolysis was measured to 0.2 µmol/g 
liver/min, and at insulin concentrations of 400 pM, glycogenolysis was 0.29 µmol/g 
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liver/min (122). However, in general insulin in thought to inhibit glycogenolysis, see 
figure 21. The data in figure 21 comes from dogs and might overestimate human 
glycogenolysis rates since the rate of hepatic glucose production is lower in dogs than in 
humans, at least in relation to hyperglycemia (28).    
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Figure 21: Rate of hepatic glycogen phosphorylase at 
increasing hepatic sinusoidal insulin concentrations, 
in conscious overnight fasting dogs (30). 
Figure 22:  Rate of hepatic glycogen synthase (GgS) 
at different insulin levels, glucose levels are held 
constant at 10 mM - Data from (129). 
  
Insulin stimulates glycogen synthesis by increasing the amount of glycogen synthase a 
(the active form) (16;129). The effect of insulin on glycogen synthesis is showed in figure 
22. At a glucose concentration of 10 mM and basal insulin the rate of glycogen synthesis 
is 0.07 µmol/g liver/min (129). This is increased about 6 fold at an insulin concentration 
of 280 pM to about 0.44  µmol/g liver/min. The stimulation of glucose synthesis by 
insulin can be described by a Hill function with a Hill constant of 20 and a half maximal 
stimulation at 170 pM. The function is very steep, which means that insulin stimulation 
almost can be seen as a switch.  
 
The effect of insulin on hepatic glucose metabolism can be subject to a time response 
(delay) of about 15 min (29).  
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Insulin also regulates gluconeogenesis (84). This regulation includes both direct and 
indirect effects (161). Indirectly, insulin inhibits gluconeogenesis through inhibition of the 
substrates; amino acids and glycerol (161).  
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4 POSTPRANDIAL LIPID METABOLISM 
Due to the metabolic disease diabetes type 1 and type 2, and the dysfunction of glucose 
metabolism observed with these diseases there has been a strong focus on quantitative 
models of glucose metabolism, for instance the minimal models.  However, as pointed out 
earlier, the regulation of fat and glucose metabolisms are connected. A decrease in the 
ability of insulin to inhibit release of fatty acids can, for instance, influence the utilisation 
of glucose; see Simulation of Hyperinsulinaemic Glucose Clamp. The literature also 
provides examples, which show that increased plasma non-estrified fatty acid is associated 
with impaired glucose uptake and decreased insulin sensitivity (12), whereas reduction in 
plasma non-esterified fatty acids is related to increased insulin sensitivity (139). The close 
relation between glucose and fat makes it interesting to focus more on the regulation of fat 
metabolism.  
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Figure 23: The figure shows the plasma non-esterified fatty acid profile for 
6 studies where a mixed meal or OGGT is given after an overnight fast. 
Data is taken from (35;63;86;113). 
 
 
 
 
When looking at models of postprandial (overnight fast followed by a meal) plasma non-
esterified fatty acids, the time scale is often 300-360 minutes (121;136). Within this time 
interval the typical behaviour for plasma non-esterified fatty acid is to decrease from an 
overnight levels of 400-600 µM to around 100-200 µM about 60 min after a meal for there 
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after to increase again towards the initial level. For illustration here of see figure 23. This 
behaviour is captured well by the models describing plasma non-esterified fatty acid 
dynamics by Periwal et al, 2009 (121)  and by Roy & Parker, 2006 (136).   
 
In two of the studies shown in figure 23, Frayn et al, 1993 and Coppack et al, 1992 
(35;63) the study is stopped after 360 min. Within this time frame the plasma non-
esterified fatty acid concentration decreases from around 500-600 µM  to around 100 µM 
about 60 min after the meal is given. Around 120-180 minutes after the meal plasma non-
esterified fatty acid concentration increases again reaching initial level at the end of the 
study.  
 
However, in the study  by  Jackson et al, 2005 (86)  and the three OGGTs by Moeri et al, 
1988 (113), the experiment was ended 480 min after the meal/OGGT was given. This 
discloses an extra dynamic effect in the plasma non-esterified fatty acid profile, where the 
plasma non-esterified fatty acid concentration keeps increasing after having reached initial 
level, and a plasma non-esterified fatty acid overshoot can be observed. The observed 
overshoot is not captured by the mentioned models of plasma non-esterified fatty acid 
dynamics, and might be due to a physiological mechanism not described by the model in 
Periwal et al, 2009 (121)  and Roy & Parker, 2006 (136).  The two models describe 
adipose tissue lipolysis, re-esterification of fatty acid into adipose tissue, and periphery 
uptake of fatty acids from plasma, as well as interaction among fatty acids, glucose and 
insulin.  
 
During a normal day meals are usually eaten with an interval of 4-6 hours, or less. 
However this does not mean that the late postprandial plasma fatty acid overshoot which 
is observed 6-8 hours after a meal, is not interesting. The metabolic response to a second 
meal is not similar to the response observed after the first meal (after an overnight fast) 
(58).  The reason for the difference between metabolic responses to the first and second 
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meal could be explained by this overshoot. Therefore, is it interesting to investigate the 
mechanism behind the late postprandial non-esterified fatty acid overshoot.  
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4.1 MODELLING PLASMA NON-ESTERIFIED FATTY ACID DYNAMICS 
In the following a model of postprandial plasma non-esterified fatty acid dynamics will be 
setup, the model will be used to examine possible mechanisms resulting in the plasma 
non-esterified fatty acid overshoot observed in studies 5-8 hours after a meal following an 
overnight fast, see figure 23. The model is also used to examine if differences, for 
example between lean and obese subjects, seen in plasma insulin, triglyceride and non-
esterified fatty acid profiles after a meal can be explained by changes in the lipid 
metabolism described by the plasma non-esterified fatty acid dynamics model. 
The model consists of eight differential equations, with 20 parameters, in which two 
represents plasma non-esterified fatty acid concentrations and interstitial non-esterified 
fatty acid concentration, the remaining six differential equations represent two systems of 
3. order delays. A schematic representation of the model is shown in figure 24, followed 
by all model equations. Non-esterified fatty acid enters plasma from the interstitial 
compartment, through diffusion, and is taken up by periphery tissue. The interstital space 
has an entry of non-esterified fatty acid both from adipose tissue lipolysis, and adipose 
 
 
Figure 24: Schematic representation of Postprandial Plasma Non-Esterified Fatty Acid Model 
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tissue lipoprotein lipase, and is removed through adipose tissue re-esterification. Non-
esterified fatty acid can also enter or be removed from the interstitial space from/to plasma 
depending on the concentration gradient. The velocity relations are described by 
michaelis-menten type functions, except the exchange between plasma and interstital 
space. The parameters for the velocity function in the model are roughly estimated within 
the indication found in the published literature.   
4.1.1 Adipose Tissue Lipolysis and Re-Esterification 
The mobilization of stored fat takes place via hydrolysis, where adipose tissue 
triglycerides are hydrolysed into three fatty acids and one glycerol, all of which are 
released into the circulation for use by other organs. The initial and rate-limiting step 
lipolysis is the hydrolysis of triglyceride to yield one non-esterified fatty acid and 
diaglyceride (50). The key enzyme of this process in adipocytes is hormone-sensitive 
lipase, although new adipose tissue triglyceridelipases have been identified (50;168). In 
the postprandial state lipolysis is regulated primarily through the antilipolytic actions of 
insulin (40;50;66;150). Insulin sensitivity of lipolysis has a considerable variation in 
healthy humans (150), with reported half maximal suppression constant (Ki) between 10 
pM to 140 pM (17;25;26;40;150). In the overnight fasted state (low insulin concentration 
~ 50 pM) the rate of lipolysis is in the order of 30 - 40 µmol/kg fat mass/min for lean 
subjects (25;26;35;165) and 20-25 µmol/kg fat mass/min for obese subjects (26;35;165). 
The rate of lipolysis decreases as insulin increases. However even at very high insulin 
concentrations (above physiological concentrations), lipolysis can be observed. This 
indicates a basal lipolysis rate. A lipolysis rate of ~13 µmol/kg fat mass/min was found for 
both lean and obese persons at insulin concentrations above 13000 pM (25;26).  
 
The function describing the adipose tissue lipase flux is shown below. The rate is 
inhibited by insulin and consists of a michaelis-menten type function dependent on insulin 
and a basal rate. The maximal velocity and the basal velocity depend on fat mass.  
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Alteration in lipolysis are frequently associated with obesity, including an increase in 
basal rates of lipolysis that may contribute to the development of insulin resistance, as 
well as an impaired responsiveness to the antilipolysic effect on insulin (50).  
 
In addition to the inhibitory effects on the enzymes in triglyceride hydrolysis, insulin also 
decreases net fatty acid release by increasing the rate of fatty acid re-estrification (39;50). 
In addition to the stimulatory effect of insulin on re-esterifiction, adipose tissue re-
esterification also depends on substrate availability that is non-esterified fatty acid 
concentration (104). During basal conditions (overnight fast) adipose tissue re-
esterification is around 20% of adipose tissue lipolysis rate, about 8 µmol/kg fat mass/min 
(25;164) in lean subjects. Half maximal rate of re-esterification is likely to occur at a non-
esterified fatty acid concentration of 1500 µM, around albumin-binding saturation range 
(104). In basal non-esterified fatty acid concentration is considered to be around 500 µM 
(66) and re-esterifiction rate 8 µmol/kg fat mass/min, then the maximal re-esterification 
rate at basal level would be around 30 µmol/kg fat mass/min. As mentioned, insulin 
stimulates the rate of adipose re-esterification. Half maximal stimulation of re-
esterification by insulin is found to be 120 pM (74). Maximal stimulation by insulin is set 
to 5, so that at basal level (overnight fast, insulin 50 pM) there are no effect of insulin on 
the re-esterification rate. The function describing the rate of adipose tissue re-
esterification in presented below. The function consists of a non-esterified fatty acids 
dependent part and an insulin dependent part. As mentioned, insulin increases the 
maximal rate of adipose tissue re-esterification approximately by five fold at maximal 
stimulation.   
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Both for lipolysis and re-esterification the effect of insulin is associated with at small 
response time in the order of 10-30 min (35;55). This response time could represent the 
diffusion of insulin across the epithelial cells and the interstices, association of adipocyte 
insulin receptors, and in-/activation of intracellular processes.(15;89). 
 
4.1.2 Lipoprotein Lipase 
Triglyceride is, unlike glucose, not soluble in the plasma. Therefore, it is transported in 
the circulation in the form of lipoprotein particles (59;66). The two major lipoproteins are 
chylomicrons (from the diet) and VLDL particles (secreted by the liver). They are both 
hydrolysed by the Lipoprotein lipase (LPL) present in the capillary bed of the endothelial 
cells in a variety of tissues for instance in adipose tissue, skeletal muscle, and heart 
(44;59;66). Adipose tissue is the tissue with the highest activity of LPL, particularly in the 
postprandial state (35). In the basal state where plasma triglyceride concentration is 
around 1000 µM, the rate of LPL are approximately 100 µmol/min (35;56). In vitro 
studies indicate a C50 of around 3000 µM (22;33). The activity of adipose tissue LPL is 
stimulated by insulin over a relatively long time-course (4-6 hours) (35;66), while in 
muscle cells it is inhibited by insulin (66). The maximal activation of LPL by insulin in in 
vitro studies of human adipocytes are reported to 7 fold with maximal stimulation at 7000 
pM insulin (3), 4.4 fold, with a EC50 of approximately 250 pM and with maximal 
stimulation at 1000 pM insulin (96). However, in in vivo studies half maximal stimulation 
of LPL by insulin was found to be at 200 pM (35;55;65).  eq. 47 shows the functional 
relationship describing the rate of adipose tissue lipoprotein lipase. Again the rate consists 
of the product of two michaelis-menten functions, one depending on plasma triglyceride 
and the other on insulin concentration. As previously mentioned, the stimulatory effects of 
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insulin are delayed in relation to the actually insulin concentration, the effective insulin 
concentration on lipoprotein lipase is denoted ILPL. In the present model this delay is 
represented by at 3.order delay, see the section “Postprandial Plasma Non-Esterified Fatty 
Acid Dynamics Model Equations” for the representation of a 3. order delay.  
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The presence of LPL on the capillary endothelium allows the lipoprotein particles passing 
through the capillary to be hydrolysed. The movement of fatty acid from the site of LPL 
action into the cells is not fully understood. It seems, however, to follow concentration 
gradients across the endothelium to the interstitial space and into the cells (59;65).   In 
adipose tissue not all fatty acids released by LPL action are taken up by the adipocytes. 
Thus, there is a spillover of non-esterified fatty acids in to plasma (55;59).  
 
4.1.3 Fatty Acid Uptake in Periphery Tissues 
The fate of the non-esterified fatty acid taken up by periphery tissue is either to undergo 
oxidation or re-esterification to triglyceride. Both oxidation and re-esterification can in 
principle take place in most tissues. In muscle fatty acids are particularly taken up in the 
oxidative fibres. Under resting condition this uptake is closely related to plasma non-
esterified fatty acid concentration, and with in the muscle cell fatty acids are oxidised in 
accordance with their rate of uptake (64). A relation between fatty acid oxidation and 
plasma non-esterified fatty acid concentration is shown in figure 25. There the relative 
rate of fatty acid oxidation (fatty acid oxidation relative to total oxidation) vs. plasma non-
esterified fatty acid concentrations from four studies (2;11;113;159) are shown. The total 
oxidation in the four studies is on average 1.2 kcal/min, with a maximal variation of ± 
25% in resting postprandial condition.   
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Figure 25: Relative fatty acid oxidation vs, plasma non-esterified fatty 
acid concentration under resting conditions. Experimental data 
(2;11;113;159) from different studies are marked, the full line represents a 
michaelis-menten type function (maximal velocity) Vm = 1  and 
(concentration for half maximal velocity)Km = 478 µM (R2 = 0.82). 
 
 
 
 
The function describing the relationship between plasma non-esterified fatty acids and 
fatty acid oxidation is shown in eq. 48.  
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eq. 48 
In the liver the two major fates of non-esterified fatty acid is re-esterification and 
oxidation (66). Complete oxidation  is small, only 4-5% (110). In vitro hepatic non-
esterified fatty acid uptake is substrate dependent and saturated at high non-esterified fatty 
acid levels. Its seems to be independent of any other nutrients or hormones (97;156). 
Maximal rate of hepatic non-esterified fatty acid uptake is around 600 µmol/min and half 
maximal rate at a concentration of 1500 µM, based on in vitro studies in rats (80). The 
function for hepatic fatty acid uptake is shown below.  
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4.1.4 Transport of Non-Esterified Fatty Acid between Adipose Tissue Interstitium 
and Plasma 
Transport of non-esterified fatty acid occurs via diffusion and/or via transport proteins. A 
number of transporters have been identified (4;79), but it is still debated whether or not 
the diffusion mechanism is the stronger. Whatever the mechanism, transport of non-
esterified fatty acid into cells is regarded to be passive (i.e. not ATP-requiring) and 
concentration driven (6;67;75). The diffusion (or transport) of non-esterified fatty acid 
between plasma and interstitium depends on the concentration gradient between the two 
compartments, and on both permeability surface area (PS) and on perfusion (BF) in 
adipose tissue. If the transportation of non-esterified fatty acid between plasma and 
interstitium is described through a mass balance function, then the flux of non-esterified 
fatty acid from plasma to interstitium can be expressed as follows:  
[ ] [ ]( )ip NEFANEFAPPDIFF −⋅=  
eq. 50 
 
For high permeability (PS >> BF) the value of PP will come close to the rate of perfusion. 
In adipose tissue the rate of perfusion is reported to be between 2 and 4 mL/100g fat 
mass/min (34) – around 0.3 L/min in a lean man (around 12 kg fat mass). Capillary 
permeability-surface area for palmitate was found to be 1.3 ml/g tissue/min at albumin 
concentrations of 0.44 mM in rabit hearts (6).   
4.1.5 Other regulatory mechanisms 
There are a number of additional regulators of non-esterified fatty acid metabolism 
besides those mentioned above. Catecholamines, cortisol and glucagon are hormones, 
other than insulin, that regulates non-esterified fatty acid metabolism (50).  As an example 
catocholamines are known to stimulate lipolysis, and although catecholamines in plasma 
do increase acutely after a meal (141), the changes are small compared to what is needed 
for at significant change in lipolysis (128). And, as the focus here is on non-esterified fatty 
acid dynamics in the postprandial state, these effects are not considered in detail. Further 
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glycolysis is needed to produce glycerol-3-phosphate required for fatty acid re-
esterification, thus it is possible that glucose can stimulate re-esterification of non-
esterified fatty acids in adipose tissue. However, in experiments examining effects of 
glucose on adipose tissue metabolism, it was not possible to distinguish the effects of 
glucose from the effects of insulin (38;41;100). Again, looking at postprandial 
metabolism, it is assumed that glycolysis is sufficient to provide for the re-esterification in 
adipose tissue.  
4.1.6 Postprandial Plasma Non-Esterified Fatty Acid Dynamics Model Equations 
and Parameters 
All model differential equations and the equations representing model fluxes and model 
parameters are collected in this section. First all model differential equations are shown, 
the first 3 differential equations represent the 3. order delay on insulin’s effect on 
lipoprotein lipase. The three differential equations describing the 3. order delay are under 
one described as eq. 51. Similar for the three equations describing the 3.order delay for 
insulin’s delayed effect on adipose tissue lipase a re-esterification, which under one is 
denoted eq. 52.  
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eq. 54 
In the following all postprandial plasma non-esterified fatty acid model fluxes are 
repeated:  
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Table 5: Postprandial Plasma Non-Esterified Fatty Acid Model Standard Parameters 
Vi  0.8 L Estimated from (99) 
Vp 3 L Estimated from (13) 
τLPL 240 min (35;66) 
τAT 30 min (35;55) 
VLPL 350  *Estimated from (35;56) 
KLPL,TG 3000 µM (22;33). 
p 5  (3;96) 
KLPL,I 200 pM (35;55;65)   
VATL 50 µmol/kg fat/min *Estimated from (25;26;35;165) 
KATL 50 µM (17;25;26;40;150) 
BATL 10 µmol/kg fat/min (25;26) 
VATR 30 µmol/kg fat/min *Estimated from (25;164) 
KATR,FA 1500 µM (104) 
q 5  Estimated from (3;96) 
KATR,I 200 pM Estimated from (74) 
PS 0.025 L/kg fat/min Estimated from  (6;34) 
VFOX 444 µmol /min** *Estimated from (2;11;113;159) 
KFOX 478 µM *Estimated from (2;11;113;159) 
VHFU 600 µmol /min *Estimated from (80) 
KHFU 1500 µM (80) 
* Estimation is based on the assumption about the mathematical relationship made here 
when describing the flux 
** For energy expenditure of 1.2 kcal/min 
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4.2 TESTING POSSIBLE MECHANISM RESPONSIBLE FOR PLASMA NON-ESTERIFIED 
FATTY ACID OVERSHOOT IN THE LATE POSTPRANDIAL PHASE 
In the late postprandial phase plasma non-esterified fatty acid exceeds the basal non-
esterified fatty acid concentration. The model presented in the section “Postprandial 
Plasma Non-Esterified Fatty Acid Dynamics Model Equations” will be used to explore 
possible mechanisms responsible for the late postprandial non-esterified fatty acid 
overshoot. One of the processes suggested to drive the plasma non-esterified fatty acid 
overshoot in the late postprandial period is the increase in plasma chylomicrons and LPL 
preference towards chylomicrons to other lipoproteins. Another process is the long time 
response on insulin stimulation of Lipoprotein lipase rate, this effect is already 
incorporated in the model.  
 
After an overnight fast chylomicron concentration is close to zero, usually less than 50 
µM (66), and after a meal it typically rises to around 400-600 µM peaking around 3-4 
hours after the meal (66). Lipoprotein lipase prefers larger particles (66;166), and in 
comparison to VLDL chylomicrons are cleared quickly from plasma. This mechanism of 
competition between VLDL and chylomicrons for LPL action is incorporated into the 
model by modifying the function describing lipoprotein lipase (eq. 47) as following: 
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eq. 55 
 
The parameter ε determines the competitive advances of chylomicrons towards 
lipoprotein lipase, the higher the value of ε the higher the affinity of chylomicrons for 
lipoprotein lipase gets in relation to VLDLs affinity for lipoprotein lipase. The affinity of 
chylomicrons toward lipoprotein lipase is found to be 50 times higher than that of VLDL 
(166). Similarly, it has been shown that removal of TG from chylomicrons is 10 time 
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greater than that form VLDL after a mixed meal (36). To explore the effort of this 
mechanism, on plasma non-esterified fatty acid dynamics in the late postprandial phase, 
the model is used to simulate postprandial non-esterified fatty acid concentrations after a 
mixed meal. To do so, data from a study measuring, among other things, plasma insulin, 
triglyceride and non-esterified fatty acid concentration regularly for 480 min after a mixed 
meal (43) are used (for more details on the study  see the section “Simulation of Mixed 
Meal”. Insulin and triglyceride are used at input to the model, and plasma non-esterified 
fatty acid concentration is used to compare to simulated plasma concentration. Plasma 
insulin and triglyceride concentration is showed in figure 26 – the points represent the 
experimental insulin and triglyceride concentrations, and the lines represent model input 
concentrations. Input concentrations are determined by linear interpolation between 
points.   
 
 
Figure 26: Plasma insulin (left) and triglyceride (right) during the postprandial phase for young healthy North 
European subjects (43). The points are the experimental measured plasma concentrations, and the lines represent 
model input concentrations. The plasma insulin and triglyceride concentration are used as input for the model 
simulation done in this section.  
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First we look at the effect of lipoprotein lipases preference towards chylomicrons, 
represented in eq. 55, without including the potential effect of lipoprotein lipases delayed 
response towards insulin. This is done by setting the response time (τLPL) to 30 min, the 
same as the time response for insulin’s effect on adipose tissue lipase and adipose fatty 
acid re-esterification (τAT). The competitive advances of chylomicrons, ε, is set to 50, and 
half maximum triglyceride concentration for lipoprotein lipase rate, KLPL,TG, is increased 
to reach a reasonable overnight fast lipoprotein lipase rate of around  100 µmol/min 
(35;56). The simulation is shown in figure 27 left. There is a small effect of including the 
competition between chylomicrons and VLDL triglyceride; however the effect is not high 
enough to capture the plasma non-esterified fatty acid overshoot seen in data. It also 
seems that the effect of the competition between VLDL and chylomicrons for hydrolysis, 
is not confined to increased lipoprotein lipase in the late postprandial phase, later than 360 
min after the meal, but rather through most of the postprandial period, see also figure 27 
right. The oscillation which can be observed in the simulation are a result of the methode 
input insulin is found. Input insulin is found by linear interpolation between the data 
 
Figure 27: Left -Simulation of postprandial plasma non-esterified fatty acid metabolism, using the modified 
model, which includes competition between chylomicrons and VLDL-triglyceride towards lipoprotein lipase. 
Model input data is from Cruz et al (2005) – North European subjects (43), see figure 26. Right - Triglyceride 
dependent part of lipoprotein lipase rate. Full line is the lipoprotein lipase described by eq. 55 and the broken line 
is lipoprotein lipase described by eq. 47. Insulin stimulation is set to 1. 
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points of time series of experimental determined insulin, in this study insulin also excibits 
small oscillation in the late phase, see figure 26 left. In figure 27 (right) lipoprotein lipase 
rate during the simulation is shown, without the stimulation from insulin. Choosing ε 
equal to one corresponds to using eq. 47 to determine model lipoprotein lipase rate.  
 
 
Figure 28: Simulation of postprandial plasma non-esterified fatty acid 
metabolism, using the modified model, which includes competition between 
chylomicrons and VLDL-triglyceride towards lipoprotein lipase. Model input 
data is from Cruz et al (2005) – North European subjects (43), see figure 26. 
 
Instead of increasing KLPL,TG, when considering the lipoprotein lipase rate with 
chylomicron/VLDL competition, insulin stimulation of lipoprotein lipase rate may be 
decreased by increasing the value of half maximal concentration for insulin stimulation, 
KLPL,I . Such a simulation is shown in figure 28.  Again there is a small effect of the 
chylomicron preferential lipoprotein lipase rate. However it seems to be biggest in the 
early phase of the postprandial period. The overall conclusion from this model is that it 
does not appear to be increased lipoprotein lipase rates due to increase in plasma 
chylomicrons after a meal that is responsible for the late postprandial plasma non-
esterified fatty acid overhoot. This conclusion is also supported by experimental data. If 
the mechanism responsible for the plasma non-esterified fatty acid overshoot, alone is the 
increase in triglyceride (especially Chylomicrons) we could not observe the late 
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postprandial non-esterified fatty acid overshoot after an OGTT, where there is no release 
of Chylomicrones. However, after an OGTT an overshoot in plasma non-esterified fatty 
acid is observed – see figure 23 Moeri 50g, Moeri 100g and Moeri 150g. Hence, there 
must be another mechanism underlying the non-esterified fatty acid overshoot.  
 
 
 
Figure 29: Simulation of postprandial non-esterified fatty 
acid dynamics with and without long time response on 
insulin effect on LPL. Again input data from Cruz et al 
(2005) – see figure 26 
 
 
 
 
Even if chylomicrons increased affinity to lipoprotein lipase compared to VLDL is not the 
responsible mechanism driving the late postprandial non-esterified fatty acid overshoot, 
the mechanism could be very interesting when investigating the dynamics of plasma 
triglycerides, VLDL and chylomicrons. After a meal there is an increase in total plasma 
triglycerides, however this increase is not only due to the delivery of chylomicrons, but 
also to an increase in other lipoproteins such as VLDL. The competitive advances of 
chylomicrons towards lipoprotein lipase, could result in a simultaneous decrease in VLDL 
clearance by lipoprotein lipase and there by an increase in plasma VLDL concentration.  
 
The other mechanism proposed to drive the late postprandial plasma non-esterified fatty 
acid overshoot is the long time response related to the effect of insulin on lipoprotein 
lipase. The model presented in the section “Postprandial Plasma Non-Esterified Fatty 
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Acid Dynamics Model Equations and Parameters” already includes insulin stimulation of 
lipoprotein lipase rate and the long time response on this stimulation. By removing the 
delay of insulin’s effect on lipoprotein lipase, the model will be used to explore if insulin 
and its delayed effect on lipoprotein lipase is the mechanism driving the late postprandial 
non-esterified fatty acid overshoot. Figure 29 shows a simulation of postprandial plasma 
non-esterified fatty acid concentration with a time response to insulin stimulation (εLPL) of 
lipoprotein lipase of 30 min and of 240 min is shown. The effect of the long time response 
is clear. The late postprandial non-esterified fatty acid overshoot is increased, and with the 
time response of 240 min the simulation non-esterified fatty acid overshoot in close to 
what can be observed experientially. The long time response also decreases plasma non-
esterified fatty acid nadir to a concentration similar to the experimental found plasma non-
esterified fatty acid nadir around one hour after the meal. This also means that the delayed 
effect of insulin on lipoprotein lipase is important during the non-esterified fatty acid 
repression phase, where insulin is high. Lipoprotein lipase rate is stimulated by insulin, 
and without the response time on this stimulation the non-esterified fatty acid suppression 
will not be as big as indicated by several studies. The increased adipose re-esterifiction is 
not high enough to accommodate the increased release of fatty acids from lipoprotein 
lipase.  
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4.3 POSTPRANDIAL PLASMA NON-ESTERIFIED FATTY ACID DYNAMICS MODEL 
PARAMETER SENSITIVITY 
The model uses plasma insulin concentration and plasma triglyceride concentration as 
input. In order to evaluate the model sensitivity to the input parameters, the steady state 
plasma non-esterified fatty acid concentration is determined for a variety of insulin and 
triglyceride concentrations see figure 30.  
 
 
Figure 30: Model simulation - steady state plasma non-esterified fatty 
acid concentration vs. insulin concentration for four different TG 
concentrations. All functions and parameters are as described in the 
section “Postprandial Plasma Non-Esterified Fatty Acid Dynamics 
Model Equations and Parameters”. Fat mass 12 kg. 
 
For healthy subjects in the basal state (overnight fast), the insulin level is typically around 
20-80 pM (60 pM (66)) and the triglyceride concentration is around 1000 µM (66). For an 
insulin concentration of 50 pM and a triglyceride concentration of 1000 µM the model 
finds the concentration of plasma non-esterified fatty acid to be 400 µM. This corresponds 
well with measured overnight fasted levels of plasma non-esterified fatty acid in humans 
(410 – 470 µM (57); 500 µM (66); 370 µM (37)). The model is especially sensitive to 
insulin concentrations between zero and 100 pM. This suggests that the steady state non-
esterified fatty acid concentration is especially influenced by the antilipolytic effect of 
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insulin on adipose tissue lipolysis. As triglyceride concentration increases the interval 
where steady state non-esterified fatty acid level is sensitive to insulin decreases.  
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Figure 31: Parameter sensitivity analysis was done using input data from the Coppack study (35), mixed meal, lean 
subjects. All model parameters are varied ± 50%. 
 
There is some uncertainty about the exact value of the model parameters, in fact it will not 
be reasonable to assume that any of the parameters has an exact value, and there is most 
certainly great variance between subject groups and even for the same person at different 
times. To evaluate the parameter sensitivity of the model simulations using data from a 
mixed meal lean subjects (Coppack study (35)) are used as input insulin and triglyceride 
concentrations (For more information about the study see section “ Simulation of Mixed 
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Meal” measured insulin and triglyceride is shown in figure 34). In the study (35) plasma 
concentrations are measured regularly until 360 min after the test meal and therefore does 
not capture the late postprandial non-esterified fatty acid overshoot. To include the  
overshoot in the sensitivity analysis insulin and triglyceride concentrations are kept at 360 
min level for simulation time later than that time point. The evaluate model parameter 
sensitivity simulations are made varying one parameter at a time, all model parameters are 
varied ± 50% from their standard value. For all simulations the same input data is used. 
Here the results of the model parameter sensitivity analysis (see figure 31) are presented 
by the value of plasma non-esterified fatty acid in three states; the overnight steady state 
plasma non-esterified fatty acid concentration (basal steady state); the minimum plasma 
non-esterified fatty acid concentration (nadir); and the maximal non-esterified fatty acid 
concentration (peak overshoot). 
 
For several of the parameters the effect of varying the parameter value is very similar. The 
result of varying the parameter is often an increase or decrease of plasma non-esterified 
fatty acid concentration in all points. As an example; look at the parameter VFOX (maximal 
 
 
 
Figure 32: Sensitivity to changes in the parameter VFOX for the dynamics of the 
postprandial non-esterified fatty acid model. The parameter FOXm was change ± 
50% from the value set in table 5. 
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fatty acid oxidation) – the pink broken line in figure 31 also shown in figure 32. Varying 
VFOX induces one of the highest changes in plasma non-esterified fatty acid concentration 
both in basal steady state, in nadir and in peak overshoot.  
 
However, it does not change the general behaviour of the model, merely shifts the plasma 
non-esterified fatty acid curve upwards or downwards. The value of the parameter VFOX 
depends on the value of whole body energy expenditure. Here it is considered constant at 
1.2 kcal/min based on data for four studies (2;11;113;159), where whole body oxidation 
was measured regularly during the postprandial phase for both lean and obese subjects at 
rest. Mean total whole body oxidation form the four studies is 1.2 and maximal variation 
of - 25% and + 30%.  
 
 
 
Figure 33: Sensitivity to changes in the parameter τLPL for the dynamics of the 
postprandial non-esterified fatty acid model. The parameter τLPL was change ± 50% 
from the value set in table 5. 
 
   
The time response for the effect of insulin effect on lipoprotein lipase (τLPL) - dark blue 
dotted line figure 31 - is the parameter that has the highest impact on the overall behaviour 
of the model. In basal steady state the value of the parameter has no influence on the 
plasma non-esterified fatty acid level. But varying τLPL induces change in non-esterified 
fatty acid concentration both in nadir and peak overshoot. Even though, the change in 
plasma non-esterified fatty acid concentration in nadir and peak overshoot is one of the 
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smaller changes induced, it is the only parameter that increases plasma non-esterified fatty 
acid nadir concentration and reduces plasma non-esterified fatty acid peak overshoot 
concentration. This is also seen for τLPL decreased to 30 min (-87.5%) as shown in the 
section “Testing Possible Mechanism Responsible for Plasma Non-Esterified Fatty Acid 
Overshoot in the Late Postprandial Phase” figure 29. It is only when decreasing the value 
of τLPL this situation occurs, when increasing τLPL nadir non-esterified fatty acid 
concentration is decreased minimally; while peak overshoot concentration is fairly 
constant – at least with in the interval of τLPL investigated here.   
 
The parameters VATL, Q, P, KATL, KATR,I and KLPL,I refer to functions connected to the 
effect of insulin on the system. Changing the VATL, Q or P will correspond to changing the 
amount of enzyme, while KATL, KATR,I and KLPL,I refer to the affinity of the enzyme to 
insulin.  
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4.4 POSTPRANDIAL PLASMA NON-ESTERIFIED FATTY ACID DYNAMICS MODEL 
SIMULATIONS 
 
The postprandial plasma non-esterified fatty acid dynamics model is used to simulate 
different studies investigating the plasma non-esterified fatty acid and insulin response 
after a meal or in connection to an oral glucose tolerance test (OGTT). Experimentally 
measured plasma insulin and triglyceride concentrations from different studies are used as 
inputs to the model. To obtain a full insulin and triglyceride profile, with an insulin and 
triglyceride concentration for every simulation time point, linear interpolation drawn 
between the measured data points is made to represent the concentrations in the time 
between measurements. With this input the model simulate a postprandial plasma non-
esterified fatty acid profile, which is compared to experimentally measured 
concentrations. For the different studies, model parameters have been changed in order to 
get simulations that correspond to the experimentally observed plasma non-esterified fatty 
acid profile. The parameters changes may help us to detect changes in the regulation of 
the metabolic system. In general, it is parameters representing the affinity of insulin 
towards different stimulatory / inhibitory effects in the model that have to be changed in 
order to obtain a simulated plasma non-esterified fatty acid profiles that are similarly to 
the experimental observed profiles.   
 
4.4.1 Simulation of Mixed Meal 
In this section the postprandial plasma non-esterified fatty acid model is used to simulate 
the dynamical response of plasma non-esterified fatty acid to a mixed meal in healthy 
subjects. With a mixed meal we mean a meal consisting of fat and carbohydrate as well as 
protein.   
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The first simulation shown here is a simulation of the results obtained by Coppack et al 
(35). This simulation is meant as a control, in order to see if the model is able to replicate 
the experimental observed plasma non-esterified fatty acid response to a meal. The study 
consists of a control group of ten healthy subjects (five female), mean age 38 years, body 
mass 66 kg, height 1.70 m, BMI 23 kg/m2 and fat mass 16 kg. The test meal contained a 
total of 3100 kJ (740 kcal), and was combined of 33.5 g fat, 93 g carbohydrate and 21.9 g 
protein. Plasma triglyceride, non-esterified fatty acid and insulin were measured in 
regularly intervals until 360 min after the test meal was given. The experimental data of 
plasma non-esterified fatty acid, insulin and triglyceride from the Coppack, et al (35) 
study of lean healthy controls is shown in figure 34, together with the model simulation of 
this study. In the plot to the left, the simulated plasma non-esterified fatty acid 
concentration can be compared with the experimental measured plasma non-esterified 
fatty acid concentration. In the this simulation all model parameters concur with the 
standard parameter set, see table 5.  The model does a good job in capturing the dynamical 
behaviour of plasma non-esterified fatty acid in the postprandial state. Shortly after the 
meal is given (time zero) the plasma non-esterified fatty acid concentration decreases 
drastically reaching a nadir of about 75 µM at around 60 min after meal time. Hereafter, 
the plasma concentration increases, in a less drastic matter, reaching a concentration close 
to the initial plasma concentration at 360 min. The study is stopped after 360 min and no 
 
Figure 34: Model simulation of plasma non-esterified fatty acid concentration after a mixed meal given to 
healthy lean subjects, Coppack et al (1992). Plasma non-esterified fatty acid from study and the simulated 
plasma non-esterified fatty acid are shown in the plot to the left. The middle and right plots show plasma insulin 
and triglyceride from the experimental study; they are used as model input. All parameters are as in table 5. 
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overshoot can be observed. However, as noted, the plasma non-esterified fatty acid 
overshoot in the late postprandial phase is often observed after 360 min.  
 
Next the model was used to simulate the postprandial plasma non-esterified fatty acid 
response after a mixed meal, given to 3 different ethnic groups, North European, South 
Asians and Latin Americans, study by Cruz, et al. (2001)(43). The study seek to 
investigate whether the higher susceptibility of coronary heart disease and diabetes in 
South Asian immigrants to the UK compared with the Caucasian population may reflect 
insulin resistance and altered postprandial lipid metabolism. The study consisted of 25 
 
Figure 35: Simulation of studies in Cruz, et al (2001)(43), mixed meal given to 3 different ethnic groups.  The 
plots in the top of the figure show model simulations and experientally measured plasma non-esterified fatty acid 
concentrations after a mixed meal. The middle and bottom plots show experientally measured insulin and plasma 
triglycerides after the mixed meal, respectively. The experiental insulin and triglyceride profiles are used as 
inputs to the model. 
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healthy men, age between 22-40 years and BMI 19-27 kg/m2. The test meal provided 52%  
of the energy as fat, 40% as carbohydrate and 8% as protein, the total energy content was 
not reported. The meal was given after a 14 hour fast, and plasma triglyceride, glucose, 
insulin and non-esterified fatty acid was measured in regularly intervals for 480 min after 
the test meal were given. Model simulation of postprandial plasma non-esterified fatty 
acids, experimental input data and experimental data for plasma non-esterified fatty acids 
for all three groups are shown in figure 35.    
 
Table 6: Changes in model parameter for simulation of the different ethnic groups (43). 
 VATL       
 µmol/kg fm/min 
KATL 
pM 
p 
 
KLPL,I 
pM 
Standard parameter 50 50 5 200 
North Europeans - 25 - - 
South Asians - 45 3.5 - 
Latin Americans 40 40 3.5 250 
 
For the model simulation of the three studies to capture the experimental observed plasma 
non-esterified fatty acid profile, parameters had to be changed for all three groups. The 
changed parameters are shown in table 6 all other parameters are as in table 5. Fasting 
plasma insulin for the North Europeans is relative low (36 pM).  This indicate high insulin 
sensitivity. Roughly fitting model plasma non-esterified fatty acid to the experimental 
measured can be done by decreasing KATL from 50 pM to 25 pM, implying increased 
affinity for insulin to inhibit adipose tissue lipase. Physiologically this also seems 
reasonably since KATL, which corresponds to EC50 for insulin inhibition on adipose tissue 
lipolysis has a considerable variation in healthy humans (150), with reported EC50 values 
between 10 pM to 140 pM (17;25;26;40;150). For the two other groups; the South Asians 
and the Latin Americans, fasting plasma insulin is 53 pM and 44 pM respectively, which 
does not indicate especially increased insulin sensitivity. However the peak insulin 
concentration, after the meal, is higher for both groups compared to the North Europeans, 
and so are plasma triglycerides (see figure 35). Despite the increased insulin and 
triglycerides responses there are no changes in the plasma non-esterified fatty acid 
response. This could indicate a reduced lipoprotein lipase rate. For the South Asian group; 
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the model could replicate the plasma non-esterified fatty acid dynamics profile by 
decreasing the stimulatory effect of insulin on the rate of lipoprotein lipase. For the Latin 
American group, the stimulatory effect of insulin was decreased further by also decreasing 
the affinity of insulin for lipoprotein lipase stimulation. If the model setup is accepted as a 
quantitative description of lipid metabolism, this simulation indicates the regulation of 
lipid metabolism is impaired in the South Asian and Latin American group.           
4.4.2 Simulation of OGTT studies 
During oral glucose tolerance tests plasma non-esterified fatty acid decreases almost 
immediately after glucose is given and minimal non-esterified fatty acid concentration can 
be observed about 30 min after peak insulin concentration. As for mixed meals, plasma 
non-esterified fatty acid concentration rebounds and overshoots its initial value, with out 
any increase in plasma triglyceride. The model is used to simulate oral glucose tolerance 
tests by  Moeri et al (1988) (113). The study includes 8 healthy men age 22 years and 
BMI 21.7 kg/m2. The amount of body fat is not reported, however a fat mass of 12 kg will 
be used. The study consisted of three OGTT; 50 g glucose, 100g and 150 g glucose. 
Plasma triglyceride concentration is not reported in the study, for the simulation the 
triglyceride concentration is considered constant at 1000 µM. Similar studies report little 
or no change in plasma triglyceride concentration during OGTT (23;91).     
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Figure 36: Experimental data from three OGTT’s  with 50 g, 100 g and 150 g glucose, in healthy subjects 
(113). Time series of plasma non-esterified fatty acid (○) and insulin (●) are shown for all three OGTT’s, 
glucose is given at time zero, and the full line is the model simulation of plasma non-esterified fatty acid. Input 
plasma triglyceride is considered constant at 1000 µM through out the simulation, since no plasma triglyceride 
is reported in the studies. 
 
 
For each of the glucose loads (50, 100, and 150 g), non-esterified fatty acids levels are 
simulated (figure 36) and compared with the experimental values. In order to get the best 
fit, some parameters were slightly adjusted from the standard parameters (the same 
parameters for all three experiments), see table 7, all other parameters are as stated in the 
standard parameters for the postprandial plasma non-estrified fatty acid model, see table 5. 
The parameter changes used for the simulation of OGTT are not unambiguous. However 
the selected combinations of parameters are those which are related to the effect of 
insulin, and are all within their physiological ranges.   
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Table 7: Changes in model parameter for simulation of OGTTs (113). 
 KATL 
pM 
q 
 
p 
 
KLPL,I 
pM 
Standard parameter 50 5 5 200 
OGTT 80 2.5 2.3 150 
 
The time series of insulin and plasma non-esterified fatty acids measured during the three 
OGTTs (113) and the model simulation of the three OGTTs shows how the drop in the 
non-esterified fatty acids level depends on the amount of glucose ingested. Ingestion of a 
high amount of glucose results in the highest AUC of insulin. The postprandial non-
esterified fatty acids dynamics can be described with four phases. In the first phase, the 
rise in insulin results in a suppression of adipose tissue lipase (ATL) and in non-esterified 
fatty acids. In the second phase, the non-esterified fatty acids levels are at its lowest while 
insulin remains high. In the third phase, the drop in insulin causes the non-esterified fatty 
acids levels to return to initial levels. In the last phase, insulin is at its initial level while 
non-esterified fatty acid concentration is increasing above its initial value. This gives an 
overshoot in plasma non-esterified fatty acids levels. This simulation of OGTT 
emphasises, the findings in the section “Testing Possible Mechanism Responsible for 
Plasma Non-Esterified Fatty Acid Overshoot in the Postprandial State” that the 
mechanism driving this overshoot is the delayed effect of insulin on lipoprotein lipase 
activity. However, the decrease in the parameters connected to insulin effect on 
lipoprotein lipase and adipose tissue re-esterification, could indicate influence of the 
plasma triglyceride concentration on the plasma non-esterified fatty acids also in the 
earlier phases of postprandial state should not be underestimated. During this simulation 
the plasma triglyceride concentration is kept constant at 1000 µM, since no plasma 
triglyceride concentration was reported in the studies.   
 
Non-esterified fatty acids oxidation is substrate dependent and decreases in the early 
phase of the OGTT. In the same way, the simulation gives a drop in hepatic non-esterified 
fatty acids uptake, data not shown. 
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4.4.3 Simulation of mixed meal studies for obese and diabetic subjects 
The last two simulations performed, with the postprandial plasma non-estrified model are 
simulations of a study of obese subjects and of obese diabetic subjects. The first study by 
Coppack et al (2002) (35), with 8 obese subjects (five female), age 45 years, BMI 42 
kg/m2, fat mass 48 kg. The test meal contained a total of 3100 kJ (740 kcal) and consisted 
of 33.5 g fat, 93 g carbohydrate and 21.9 g protein. Plasma triglyceride, non-esterified 
fatty acid and insulin were measured in regularly intervals 360 min after the test meal was 
given. The second study simulated is by Tan et al (2005) (151). It included 24 obese 
subjects with type 2 diabetes, fasting glucose between 7-12 mM, none were taking any 
 
 
Figure 37: Simulation of postprandial non-esterified fatty acid dynamics of obese subjects from Coppack et al 
(1992)(35) and obese subjects with type 2 diabetes (DM) from Tan et al (2005)(151).  Fat mass 48 kg for the 
obese and 40 kg the obese DM group (Fat mass not reported in Tan et al (2005), the used fat mass is estimated 
based on BMI). The only parameter changed from the standard is KATL = 110 pM. 
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medication known to affect glucose metabolism. All subjects in the study were between 
30-70 years and with a BMI 32.8 kg/m2. Fat mass was not reported in the article, but in 
the simulation it is set to 40 kg, estimated on basis of BMI.  
 
Table 8: Changes in model parameter for simulation of Coppack et al (1992) obese and Tan 
et al (2005) obese diabetics.  
 KATL 
pM 
Standard parameter 50 
Coppack – obese 110 
Tan – obese diabetic 110 
 
For the model simulation of the obese and obese diabetic subjects to be compatible to 
measured plasma non-esterfied fatty acid concentrations, it required an increase in the 
insulin concentration for half maximal suppression of adipose tissue lipase, KATL. The 
high KATL concentration is in good agrement with the failure to suppress adipose tissue 
lipolysis in the normal manner, in response to postprandial hyperinsulinemia, which is 
often related to obesity (90).  The increased insulin concentration for half maximal 
suppression of adipose tissue lipase, KATL, for obese is in accordance with the clinical 
observed (25;26). Unfortunately the duration of the studies simulated are not long enough 
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Figure 38: Relation between model parameter KATL and 
fasting insulin level. 
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to capture the plasma non-esterified fatty acid overshoot, as so we can not detect any 
changes in the regulation of lipoprotein lipase.  
 
 
Common for all simulations shown above are that the parameter for half maximal 
inhibition of adipose tissue lipase (KATL) can be determined based on the level of basal 
insulin.  
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4.5 DISCUSSION AND CRITIQUE OF THE POSTPRANDIAL PLASMA NEFA DYNAMICS 
MODEL 
The ability of the model to describe early postprandial plasma non-esterified fatty acid 
dynamics is fairly good. However several models are published which can describe this 
behaviour. Common for other models of non-esterified fatty acid metabolism (121), 
including the one described here, is the high inhibitory effect of insulin on adipose tissue 
lipase. When modelling different subjects/patient groups changing the parameter KATL, 
which describes insulin affinity for adipose tissue lipase, will make the model reaching 
compatible plasma non-esterified fatty acid levels. Moreover changing this parameter, in 
order to fit model simulation to data, seems reasonable since physiological realistic 
interval is very large.  The model simulations shown above reveal a relation between the 
overnight fasted insulin concentration and the value of KATL. Low overnight fasted insulin 
concentration seems to require a high affinity of adipose tissue lipase towards insulin (low 
KALT value), see figure 35 – North Europeans. While high overnight fasting insulin 
concentration, as for obese subjects (see figure 37), seem to require a lower affinity of 
adipose tissue lipase towards insulin (high KATL values).   
 
For the late postprandial period the current model is able to capture the plasma non-
esterified fatty acid overshoot. According to this model the dynamics of this overshoot is 
controlled by the lipoprotein lipase, its sensitivity to insulin and, very importantly, the 
large response time in connection to the stimulatory effect of insulin on lipoprotein lipase. 
In relation to the lipoprotein lipase, the model is used to test if the effect of different 
lipoproteins on lipoprotein lipase is responsible for driving the late postprandial plasma 
non-esterified fatty acid overhoot. Chylomicrons are reported to have 50 fold higher 
affinity towards lipoprotein lipase than of VLDL. It was found that this mechanism could 
no explain the late postprandial plasma non-esterified fatty acid overshoot. However, in 
this connection it is important to note that the form of the function describing the 
competition between chylomicron-triglyceride and VLDL-triglyceride towards lipoprotein 
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lipase (eq. 55), is very simple. The advance of chylomicron-triglyceride is described by 
increasing the apparent chylomicro-triglyceride concentration, in relation the real 
chylomicron-triglyceride concentration. A more correct relation would be to use the 
michaelis-menten function for competitive inhibition. The function looks as follows: 
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eq. 56 
where v is the reaction rate, Vmax the maximal velocity, and [S] the substrate concentration. 
Km is the half maximal velocity concentration of substrate, [I] the inhibitor concentration, 
and Ki is the inhibition constant. But the required information about the kinetics for the 
rate of chylomicron-triglyceride removal by lipoprotein lipase was not found. 
 
The model was used to identify the mechanism responsible for the late postprandial 
plasma fatty acid overshoot observed experimentally. However it was not possible to use 
the model to investigate if this overshoot can account for the difference between the 
metabolic response to the first meal after an overnight fast and the second meal. This was 
not possible due to lack of data, the model needs plasma insulin and triglyceride as input, 
and it was not possible to find at study where these variables were measured and reported 
for both the first and the second meal. 
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5 ADIPOSE TISSUE DISTRIBUTION 
Fat accumulation in the visceral area is believed to be particularly dangerous because it is 
highly correlated with cardiovascular and metabolic risk factors such as elevated blood 
pressure, dyslipidemia, insulin resistance, and type 2 diabetes (10;47;60;162). Thus, 
reduction of visceral adipose tissue (VAT) may be especially beneficial. Fortunately, 
negative energy balance appears to cause VAT to decrease faster than total fat mass (FM) 
(145) which may explain the early metabolic benefits of weight loss. But are some weight 
loss methods better than others at generating a targeted or selective reduction of VAT?  
5.1 ALLOMETRIC RELATIONSHIP BETWEEN CHANGES OF VISCERAL FAT AND 
TOTAL FAT MASS  
Several years ago, Smith et al. addressed the issue of selective reduction of VAT by 
reviewing published studies that measured VAT as well as total fat mass (FM) changes 
during weight loss and found that most weight loss interventions caused a preferential loss 
of VAT (145). These authors concluded that the absolute amount of VAT loss was related 
to both the amount of FM loss as well as the initial VAT (145), but a clear mathematical 
relationship between these variables was not determined.  
 
This study updates and extends the observations of Smith et al. (145) and test the 
hypothesis that changes of VAT mass and FM are allometrically related according to the 
following differential equation: 
 
FM
VATk
dFM
dVAT
⋅=  
 
eq. 57 
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where k is a dimensionless constant and VAT and FM denote the initial values of visceral 
adipose tissue and total fat mass. This class of equation has a long and rich history and 
was first used by Huxley to describe the law of constant differential growth between 
various body parts of an organism (85). It is shown that this allometric relationship 
accurately describes the published data on changes of VAT and FM and that the same 
relationship holds regardless of gender or the type of weight loss intervention.  
5.1.1 Method 
Published studies were included in this analysis if FM and VAT were measured before 
and after a weight loss intervention in humans, regardless of the method of weight loss. 
Total fat mass was measured by dual energy X-ray absorptiometry (DEXA), underwater 
weighing, and air displacement plethysmography, via whole-body computed tomography 
(CT) or via magnetic resonance imaging (MRI). Studies measuring FM changes using 
bioelectric impedance or anthropomorphic methods, such as skin-folds, were excluded. 
MRI or CT imaging was used to assess VAT changes.  
 
Since the hypothesized allometric equation is an expression involving VAT mass, 
converting cross-sectional VAT areas to volumes using the regression equations described 
by Shen (144) was done. (This procedure was unnecessary for studies that measured VAT 
volumes using multi-slice CT or MRI.) Since different regression equations are used to 
convert cross-sectional areas to volumes in men and women, it was required that the 
studies report the VAT areas for men and women separately. Furthermore, the regression 
equations required that the slice location had to be either at L4-L5 for either genders or 5 
cm above L4-L5 for women and 10 cm above L4-L5 for men. L4-L5 referrer to the L4-L5 
intervertebral space in the spinal cord. This is in the lower part of the spinal cord.  We 
assumed an adipose tissue density of 0.93 kg/L. 
 
A search for studies matching the above inclusion criteria in both PubMed and Web of 
Science databases using the search term “weight loss visceral adipose tissue” was done. 
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On July 4th 2007, the PubMed search returned 83 hits and the Web of Science search 
returned 335 hits, 65 of which were duplicates also found in the PubMed search. 
Examination of the abstracts reduced the number of studies possibly matching the search 
criteria to 131. Investigation of the methods sections of these remaining reports further 
narrowed the number of studies to a total of 34 that fulfilled the inclusion criteria. The 
citations from these 34 reports were then surveyed for studies not found by the initial 
search, and resulted in an additional 3 studies such that 37 total studies matched the 
inclusion criteria.  
 
In appendix A, it is shown that the allometric hypothesis requires that the ratio of the 
change of VAT to the change of FM, FMVAT ∆∆ , is proportional to the initial ratio of 
VAT to FM, VAT/FM .Therefore, these ratios were calculated and it was investigated 
whether or not a linear relationship existed. Typically, such an analysis would be 
completed using a weighted least-squares linear regression method that assumes that only 
the y coordinate is associated with uncertainty. However, in the present case this cannot 
be assumed since the data had uncertainties in both the x and y coordinates. Therefore a 
combination of the use of traditional weighted linear regression, which accounts for the 
uncertainties in the y direction, along with a Monte-Carlo strategy to take the uncertainties 
in the x direction into account, was used. For each Monte-Carlo iterate, a random set of x 
variables was chosen such that each x value was normally distributed about the data point 
with a standard deviation given by the uncertainty of each data point. For each Monte-
Carlo iteration, a weighted least-squares regression procedure to fit to the line y = k*x 
were performed. The model parameter k was estimated as the average over 10000 Monte-
Carlo simulations. All model statistics were then assessed based on this average linear 
model. Outlier assessment based on the Cook’s distance and studentized residuals were 
calculated using the standard deviations of the data points.  
 
The x variable (initial VAT/FM) and y variable (∆VAT/∆FM) in the analysis were 
transformations of the reported VAT and FM data. Since the initial VAT and FM 
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measurements were included in both x and y variable calculations, the data transformation 
introduced dependences between the variables that could possibly lead to spurious 
correlations (19). The analysis also included testing for spurious correlations by randomly 
shuffling the VAT and FM measurements 10000 times and calculated the coefficients of 
determination (i.e., the Pearson correlation coefficient squared, r2) of the resulting x and y 
variables. If the data transformation procedure itself introduced significant correlations, 
then the r2 calculated using the shuffled data should frequently exceed the r2 determined 
from the un-shuffled data. The probability of a spurious correlation was estimated as the 
fraction of the 10000 r2 values obtained using the shuffled data that exceeded the observed 
r2 value of the original un-shuffled data. 
5.1.2 Results 
The systematic review produced a total of 37 weight loss intervention studies, 
representing 1407 subjects and 79 data points (see appendix B for table of data included in 
this study). The population comprised 24% men and 73% women, of which 27% were 
postmenopausal. The number of gender was not reported for 3% of the subjects. These 
studies investigated a wide range of weight loss interventions including caloric restriction 
(20;31;48;49;68;69;71;73;87;88;98;116;117;126;127;131-134;138;140;152;154;157;163), 
endurance exercise (12;46;53;69;98;102;115-117;119;126;131-
134;137;138;143;153;154), resistance exercise (87;88;127;130;134), and bariatric surgery 
(24;70;101). One study reported data from women with type 2 diabetes (T2DM) (69) and 
another study investigated HIV positive women (53).   
 
The loss of visceral fat mass relative to the total loss of fat mass (∆VAT/∆FM) was potted 
against the initial visceral fat mass divided by the total fat mass (VAT/FM).  Figure 39 
clearly shows a linear relationship between these two ratios which is consistent with our 
hypothesis that VAT and FM changes are allometrically related. The calculated 
dimensionless model parameter was k = 1.3 ± 0.1 with an R2 = 0.73 indicating that the 
model explained more than 70% of the variability in the reported data. We found no  
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evidence of spurious correlations since none of the 10000 shuffled VAT and FM data sets 
produced a coefficient of determination higher than that observed for the original data. 
The residuals of the model, plotted in figure 39 right, indicate no general trend. There 
were no outliers detected by examination of Cook’s distance (maximum value was 0.04) 
or studentized residuals (maximum magnitude was 1.05). The chi-square was 4.6 and, 
based on an evaluation of the incomplete gamma function, the probability is less than 10-33 
that the chi-square for a correct model should be less than the chi-square calculated for 
this model (123). In other words, the allometric model provides an excellent fit to the data. 
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Figure 39: Left - Changes of visceral fat mass relative to the change of total fat mass 
(∆VAT/∆FM) versus the initial visceral fat mass divided by the total fat mass (VAT/FM) as 
compiled from 37 published studies of weight loss representing more than 1400 subjects. Male 
subjects (♦) had higher initial VAT to FM ratios compared to healthy pre-menopausal women 
(□), post-menopausal women (∆), HIV positive women (◊), or women with type 2 diabetes 
(○). Crosses (+) indicate studies that reported a mixture of men and women. The line 
corresponds to the best fit allometric relationship to the weight loss data with k = 1.3 ± 0.1 and 
R2 = 0.73. Data from two weight gain interventions (*) are also plotted. Right - Residuals of 
the best fit allometric model versus the initial VAT to FM ratio. 
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Nevertheless, this measure of the model fit may be somewhat overestimated since the 
uncertainties for each data point were large due to the fact that access to data was limited 
to the reported group averages in each published study.  (The average calculated 
uncertainty of the data points was 05.0ˆ =xσ  and 3.0ˆ =yσ  in the x and y directions, 
respectively.) For clarity, the error bars are omitted from the figures. 
 
Both men and women were described by the same allometric relationship, where k = 1.3 ± 
0.2 for both groups calculated separately which was the same as the overall best fit line 
with k = 1.3 ± 0.1. However, the male subjects on average had a higher initial VAT to FM 
ratio as indicated by the closed black diamonds (♦) in comparison to the open symbols 
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Figure 40: Left -The same data as in Figure 1 are represented according to the type of weight 
loss intervention as follows: caloric restriction alone (□), caloric restriction with aerobic exercise 
(♦), caloric restriction with resistance exercise (+), exercise alone (∆), and bariatric surgery (○). 
Data from two weight gain interventions (*) are also plotted. Right - Residuals of the best fit 
allometric model versus the initial VAT to FM ratio. 
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(women) in figure 39 left. Crosses indicate studies that reported a mixture of men and 
women (+).  
 
Figure 40 (left and right) depicts the same data coded by weight loss intervention. The 
allometric relationship applied equally well to all weight-loss interventions as can be seen 
from the fact that no particular intervention deviated systematically from the overall best 
fit line with k = 1.3 ± 0.1. The calculated allometric constants determined separately for 
each group were no different from the overall best fit value since k = 1.2 ± 0.2 for caloric 
restriction alone (□), k = 1.4 ± 0.2 for caloric restriction with aerobic exercise (♦), k = 1.3 
± 3 for caloric restriction with resistance exercise (+), k = 1.5 ± 0.7 for exercise alone (∆), 
and k = 1.4 ± 1 for bariatric surgery (○).  
5.1.3 Discussion of Allometric Relationship 
VAT is often considered to be a labile fat depot based on the observed preferential loss of 
VAT with weight loss (145), along with the in vitro observations that visceral adipocytes 
are more lipolytically active (108;112), and are therefore believed to have a higher fat 
turnover rate when compared with subcutaneous adipocytes. Others have hypothesized 
that VAT is a secondary fat storage pool that accumulates during positive energy balance 
only after subcutaneous stores are full (146). Some have suggested that exercise 
specifically mobilizes VAT as a result of preferential stimulation of VAT lipolysis (114). 
Here, it is demonstrated that the VAT changes in parallel with FM changes and that the 
magnitude of VAT change is primarily determined by FM change according to an 
allometric relationship and does not depend on the method of weight loss.  
 
Allometric equations have historically been used to describe relationships between the 
relative growth of various body parts of an organism (85). To see this, eq. 57 can be 
rearranged as follows: 
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dt
dFM
FM
k
dt
dVAT
VAT
11
⋅=  
eq. 58 
 
thereby indicating that the relative growth rates of VAT and FM are proportional to each 
other. The fact that the best fit value of the constant k was greater than 1 (i.e., k = 1.3 ± 
0.1) corresponds to the observation of preferential VAT changes versus FM changes. The 
fact that this same value for k adequately describes both genders as well as a wide variety 
of weight loss interventions suggests that differences between men and women can be 
explained by the initial VAT to FM ratio and there is no preferential benefit of one weight 
loss intervention over another.  
 
Also data matching our inclusion criteria from two weight gain interventions was found, 
one examining recovery of anorexic women (109) and the other was an overfeeding study 
of healthy young men (18). These weight gain data also appeared to follow the allometric 
relationship as depicted by asterisks (*) in figure 39 and figure 40, but they were not used 
in the model fitting procedure. Future work should investigate the applicability of the 
allometric relationship in weight gain studies.  
 
In their 1999 review of VAT changes with weight loss, Smith et al. introduced a 
selectivity index to facilitate comparisons between weight loss interventions and quantify 
their ability to selectively target VAT (145). The selectivity index was defined as the 
percent change of VAT divided by the percent change of FM which is mathematically 
identical to the allometric constant k. The observation that the same value of k adequately 
represented various types of weight loss interventions conforms to Smith et al.’s 
conclusion that no clear pattern was detected for the selectivity index across the 
interventions (145). However, Smith et al. claimed that the selectivity index depended on 
the initial proportion of visceral fat in a subset of studies that reported single slice area 
ratios of initial VAT to subcutaneous adipose tissue (SAT). In this subset of data, also a 
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weak positive correlations between the selectivity index with both the initial VAT/FM and 
VAT/SAT (r2 = 0.26 and 0.29, respectively) was found. However, there is a high 
probability that these correlations were spurious since shuffled data produced higher r2 
values than the un-shuffled data 15% of the time. Furthermore, the autors found no 
significant correlations of the selectivity index as a function of initial VAT/FM in the full 
dataset (r2 = 0.03). Thus, the data are consistent with a constant selectivity index identical 
to the allometric constant k which is independent of the initial proportion of VAT.  
 
The allometric equation (eq. 57) can be integrated to give a power law relationship: 
 
kFMbVAT ⋅=  
 eq. 59 
 
where b is a parameter that sets the baseline amount of VAT for a given initial FM. Unlike 
many reported allometric relationships, the value of b is not a universal constant in this 
case. Rather, b depends on gender as well as other potential factors that contribute to 
determining the baseline VAT. Thus, the typical log-log plots often used to assess 
allometric relationships in this case produces a scatter of points since the values of the 
parameter b vary widely across race and gender groups (not shown).  
 
The allometric model also predicts that VAT is lost preferentially compared with 
subcutaneous adipose tissue (SAT) with modest weigh loss, but the effect is attenuated 
with greater weight loss, which is documented in the literature (27). For a more 
comprehensive description of this conclusion see appendix A.  
 
The most obvious limitation of the present analysis is that the calculated uncertainties of 
the data points are quite large due to the fact that we only had access to the reported 
average values from the published studies. Future studies should investigate these 
relationships using data on body composition change in individual subjects. Despite this 
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limitation, a clear relationship was apparent in the data and the allometric model described 
this relationship remarkably well. This analysis therefore suggests that changes of VAT 
mass are determined primarily by FM changes as well as the initial ratio of VAT to FM 
and is independent of gender or the method of weight loss intervention. In conclusion, it is 
suggested that future investigation should use the allometric model prediction as a null 
hypothesis to test for an additional independent effect of weight loss on visceral fat loss.  
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6 DISCUSSION AND CONCLUSION  
The five models described here were used to investigate different aspects of glucose and 
fat metabolism and the regulation of the two metabolic pathways. The models were 
applied both to look for relations between hormones and metabolic fluxes, and to identify 
mechanism relevant for specific metabolic phenomena.  
 
The glucose and fat metabolism steady state model illustrated the importance of 
considering the interplay between the two metabolic pathways when interpreting 
experimental results from, for example, glucose clamp studies. Fat metabolism in 
indirectly regulated by glucose metabolism through insulin, and glucose metabolism is 
regulated indirectly by fat metabolism through the rate of glucose oxidation. The glucose 
and fat steady state model combined with the simple model of hexokinase showed the 
different aspects in the regulation of glucose transport, and it was pointed out that glucose 
transport and its stimulation by insulin is not the only processes to consider when 
describing plasma glucose concentrations. It is equally important to consider glucose 
utilisation within the cells. This could be oxidation, lactate formation, lipogenesis or 
glycogen formation.  
 
The next model described in this thesis, involves the formation and breakdown of 
glycogen in the liver. The hepatic glucose metabolism model was used to demonstrate the 
regulatory effect of glucose on both glycogen synthesis and glycogen breakdown is 
necessary to describe the relation between glucose concentration and hepatic glucose 
output, under conditions similar to the overnight fasted state (insulin and glucagon at basal 
level). This section also showed that the rate of glycogen synthesis and breakdown is 
regulated by glycogen it self. Although it was not possible to identify the mechanism 
behind this regulation, it could only be concluded that both glycogen inhibition of 
glycogen synthase and glycogen stimulation of glycogen phophorylase can explain the 
relation between net glycogen synthesis/breakdown observed experimentally.  
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The postprandial plasma non-estrified fatty acid model was used to identify the 
mechanism responsible for the experimentally observed late postprandial plasma fatty 
acid overshoot. The model showed that the overshoot can be explained by insulin delayed 
effect on lipoprotein lipase and not by the differential affinity of lipoprotein lipase 
towards chylomicron-triglyceride and VLDL-triglyceride as otherwise suggested in the 
literature (9). Although the mechanism responsible for the late postprandial fatty acid 
overshoot was identified in was not possible to investigate if this overshoot can explain 
the experimentally observed difference between the metabolic response to the first meal 
and the second meal  after an overnight fast (58).  
 
The postprandial plasma non-esterified fatty acid model was able to replicate different 
studies of postprandial plasma fatty acid dynamics. However, only with a change in some 
of the model parameter values. It was found the a linear relation between overnight fasted 
insulin concentration and the parameter KATL, which is related to the affinity of insulin 
towards adipose tissue lipase, could explain some of the changes in fat metabolism for the 
different subject groups.   
 
The last model included in this thesis describes the allometric relationship between 
visceral fat and total fat mass. This is the first model to reveal an allometric relationship 
between changes of visceral and total fat mass that holds for both genders as well as for a 
wide variety of weight loss interventions including bariatric surgery, caloric restriction 
with or without exercise, and exercise alone. From this relationship it can be concluded 
that changes of visceral fat are primarily determined by total fat mass changes and bythe 
initial visceral to total fat mass ratio. For future investigations of visceral fat loss the 
allometric model predictions could be used as a null hypothesis to test for an additional 
independent effect of weight loss. 
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